{
  "symbol": "BPTH",
  "company_name": "Bio-Path Holdings",
  "ir_website": "https://www.biopathholdings.com/investors/",
  "structured_data": [
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://www.biopathholdings.com/investors/sec-filings/",
          "content": "[![Bio-Path Holdings](/wp-content/uploads/2021/09/BPTHlogo.png)](https://www.biopathholdings.com/)\n\n  * [About Bio-Path](https://www.biopathholdings.com/about/)\n    * [Overview](https://www.biopathholdings.com/about/)\n    * [Leadership](https://www.biopathholdings.com/about/leadership/)\n    * [Board of Directors](https://www.biopathholdings.com/about/board-of-directors/)\n    * [Scientific Advisory Board](https://www.biopathholdings.com/about/scientific-advisory-board/)\n    * [Partnering Opportunities](https://www.biopathholdings.com/about/partnering-opportunities/)\n  * [Technology](https://www.biopathholdings.com/technology/)\n  * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Prexigebersen](https://www.biopathholdings.com/pipeline/prexigebersen/)\n    * [BP1001-A](https://www.biopathholdings.com/pipeline/bp1001-a/)\n    * [BP1002](https://www.biopathholdings.com/pipeline/bp1002/)\n    * [BP1003](https://www.biopathholdings.com/pipeline/bp1003/)\n  * [Patients](https://www.biopathholdings.com/patients/)\n  * [Investors](https://www.biopathholdings.com/investors/)\n    * [Overview](https://www.biopathholdings.com/investors/)\n    * [SEC Filings](https://www.biopathholdings.com/investors/sec-filings/)\n    * [Corporate Governance](https://www.biopathholdings.com/investors/corporate-governance/)\n  * [Media](https://www.biopathholdings.com/media/)\n    * [Press Releases](https://www.biopathholdings.com/media/)\n    * [Events](https://www.biopathholdings.com/media/events/)\n    * [Presentations & Publications](https://www.biopathholdings.com/media/presentations-publications/)\n  * [Careers](https://www.biopathholdings.com/careers/)\n  * [Contact Us](https://www.biopathholdings.com/contact-us/)\n\n\n\n[November 25, 2024SEC Form 8-K: Other Events](https://www.biopathholdings.com/wp-content/uploads/2024/11/BPTH_8-K_20241125.pdf)\n\n[November 15, 2024SEC Form 8-K: Press Release dated November 15, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/11/BPTH20241115_8-K-1.pdf)\n\n[November 15, 2024SEC Form 10-Q: For Period ending September 30, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/11/BPTH_20241114_10-Q.pdf)\n\n[October 29, 2024SEC ARS: Annual Report 2023](https://www.biopathholdings.com/wp-content/uploads/2024/10/BPTH_20241024_ARS.pdf)\n\n[October 29, 2024SEC Form DEFA-14A: Additional Proxy Materials](https://www.biopathholdings.com/wp-content/uploads/2024/10/BPTH_20241025_DEFA14A.pdf)\n\n[October 29, 2024SEC DEF-14A: Proxy Statement](https://www.biopathholdings.com/wp-content/uploads/2024/10/BPTH_20241025_DEF_14A.pdf)\n\n[October 23, 2024SEC Form 424b3 Prospectus – October 23, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/10/BPTH._424B3_20241023.pdf)\n\n[October 21, 2024SEC Form 14A: Preliminary Proxy Statement](https://www.biopathholdings.com/wp-content/uploads/2024/10/BPTH_PRE_14A.pdf)\n\n[October 10, 2024SEC Form 8-K: Press Release dated October 10, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/10/BPTH_20241010_8-K_EDGAR.pdf)\n\nLoad More\n\n[September 13, 2024SEC For 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.biopathholdings.com/wp-content/uploads/2024/09/BPTH__20240913_8-K.pdf)\n\n[August 21, 2024SEC Form 8-K: Press Release dated August 21, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/08/BPTH__20240821_8-K.pdf)\n\n[August 15, 2024SEC Form 8-K: Press Release dated August 15, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/08/BPTH_20240815_8-K.pdf)\n\n[August 15, 2024SEC Form 10-Q for period ending June 30, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/08/BPTH_2nd_Qtr_20240814_10-Q.pdf)\n\n[July 11, 2024SEC Form 8-K: Press Release dated July 8, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/07/BPTH_8-K_07112024.pdf)\n\n[June 14, 2024SEC Form 8-K: Press Release dated June 14, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/06/BPTH_Form_8-K_06-14-24_Press_Release.pdf)\n\n[June 14, 2024SEC Form 424b3 Prospectus – June 14, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/06/BPTH_Prospectus_Resale_June_2024_PIPE.pdf)\n\n[June 14, 2024SEC Form 8-K: re Nasdaq Extension](https://www.biopathholdings.com/wp-content/uploads/2024/06/BPTH_Form_8-K_Nasdaq-Extension.pdf)\n\n[June 11, 2024SEC Form S-3](https://www.biopathholdings.com/wp-content/uploads/2024/06/BPTH_Form_S-3_Resale_Registration_Statement_20240611_PIPE.pdf)\n\n[June 5, 2024SEC Form 8-K: Press Release dated June 5, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/06/BPTH_8-K_20240605.pdf)\n\n[June 3, 2024SEC Form 8-K: Press Release dated June 3, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/06/BPTH_20240602_8-K.pdf)\n\n[May 30, 2024SEC Form 8-K: Press Release dated May 23 & May 24, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/05/BPTH_20240530_8-K.pdf)\n\n[May 15, 2024SEC Form 8-K: Press Release May 15, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/05/BPTH-Form_8-K_Q1-2024_Earnings_Release.pdf)\n\n[May 15, 2024SEC Form 10-Q for Period ending March 31, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/05/BPTH-Form_10-Q_Q1_2024.pdf)\n\n[April 24, 2024SEC Form S-1 dated April 24, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/04/BPTH_S-1_20240424.pdf)\n\n[April 19, 2024SEC Form 8-K: Other Events](https://www.biopathholdings.com/wp-content/uploads/2024/04/BPTH_20240419_8-K-2.pdf)\n\n[April 19, 2024Prospectus Supplement (To Prospectus dated June 14, 2022) 424B5 S-3](https://www.biopathholdings.com/wp-content/uploads/2024/04/BPTH_20240419_424B5_Preliminary-Prospectus_S-3.pdf)\n\n[April 19, 2024SEC Form 8-K: Entry Into a Material Definitive Agreement.](https://www.biopathholdings.com/wp-content/uploads/2024/04/BPTH_8-K_20240419.pdf)\n\n[April 19, 2024Prospectus Supplement (To Prospectus dated June 14, 2022)](https://www.biopathholdings.com/wp-content/uploads/2024/04/BPTH_424b5_2024-04-18.pdf)\n\n[April 18, 2024SEC Form 8-K: Press Release dated April 18. 2024](https://www.biopathholdings.com/wp-content/uploads/2024/04/BPTH_Form_8-K_PR_20240418.pdf)\n\n[April 15, 2024SEC Form 8-K: Press Release dated April 15, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/04/BPTH_Form_8-K_PR_20240415.pdf)\n\n[April 4, 2024Prospectus Supplement (April 2024 ATM)](https://www.biopathholdings.com/wp-content/uploads/2024/04/BPTH_Prospectus-Supplement_20240404_ATM.pdf)\n\n[April 4, 2024SEC Form 8-K: Entry into a Material Definitive Agreement.](https://www.biopathholdings.com/wp-content/uploads/2024/04/BPTH_Frm_8-K_20240404.pdf)\n\n[March 27, 2024SEC Form 424(b)5: Perspectus Supplement (To Prospectus dated June 14, 2022)](https://www.biopathholdings.com/wp-content/uploads/2024/03/BPTH._424B5_20240327.pdf)\n\n[March 27, 2024SEC Form 8-K: Other events, Financial Statements and Exhibits](https://www.biopathholdings.com/wp-content/uploads/2024/03/BPTH-_Form_8-K_20240327.pdf)\n\n[March 26, 2024SEC Form 8-K: Entry into Definitive Material Agreement](https://www.biopathholdings.com/wp-content/uploads/2024/03/BPTH_8-K_20240326.pdf)\n\n[March 13, 2024SEC Form 8-K: Nasdaq delisting notification](https://www.biopathholdings.com/wp-content/uploads/2024/03/BPTH_Form_8-K_Nasdaq_delisting_notification.pdf)\n\n[March 13, 2024SEC Form S-1 Amendment #1 Exhibits only filing](https://www.biopathholdings.com/wp-content/uploads/2024/03/BPTH_S-1_A_2024-03-13.pdf)\n\n[March 11, 2024SEC Form 8-K: Regaining Nasdaq Compliance](https://www.biopathholdings.com/wp-content/uploads/2024/03/BPTH_Form_8-K_2024_Nasdaq_Notice_re_Regaining_Compliance.pdf)\n\n[March 8, 2024SEC Form 8-K: Press Release dated March 8, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/03/BPTH_-Form-8-K_20240308.pdf)\n\n[March 8, 2024SEC Form S-1](https://www.biopathholdings.com/wp-content/uploads/2024/03/BPTH__S-1_20240308.pdf)\n\n[March 8, 2024SEC Form 10-K for Year ended December 31, 2023](https://www.biopathholdings.com/wp-content/uploads/2024/03/BPTH_10-K_2023.pdf)\n\n[February 23, 2024SEC Form 8-K: Press Release dated February 21, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/02/BPTH_Form_8-K_Reverse_Stock_Split.pdf)\n\n[February 2, 2024SEC Form 8-K: Reconvened Special Meeting](https://www.biopathholdings.com/wp-content/uploads/2024/02/BPTH_Form-8-K_Reconvened_Special_Meeting_20240130.pdf)\n\n[January 24, 2024SEC Form DEFA-14A: Definitive Additional Materials – Jan 24, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/01/BPTH_DEFA14A_20240124.pdf)\n\n[January 23, 2024SEC Form S-1A: Amendment No. 1 to Form S-1](https://www.biopathholdings.com/wp-content/uploads/2024/01/BPTH_S-1_A_20240123.pdf)\n\n[January 23, 2024SEC Form 8-K: Special Meeting](https://www.biopathholdings.com/wp-content/uploads/2024/01/BPTH_Form-8-K_Special_Meeting_20240122.pdf)\n\n[January 17, 2024SEC Form DEFA-14A: Definitive Additional Materials](https://www.biopathholdings.com/wp-content/uploads/2024/01/bPTH_DEFA14A-20240117.pdf)\n\n[January 10, 2024SEC Form 8-K: Press Release dated January 10, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/01/BPTH_-Form_8-K_20240110.pdf)\n\n[January 4, 2024SEC Form 14A: Definitive Proxy Statement](https://www.biopathholdings.com/wp-content/uploads/2024/01/BPTH_DEF_14A_20240104.pdf)\n\n[December 22, 2023SEC Form 14A: Preliminary Proxy Statement](https://www.biopathholdings.com/wp-content/uploads/2023/12/BPTH_PRE_14A_20231222.pdf)\n\n[December 22, 2023SEC Form S-1](https://www.biopathholdings.com/wp-content/uploads/2023/12/BPTH_S-1_20231222.pdf)\n\n[December 15, 2023SEC Form 8-K: 2023 Annual Meeting](https://www.biopathholdings.com/wp-content/uploads/2023/12/BPTH_Form_8-K_2023_annual_meeting.pdf)\n\n[December 14, 2023SEC Form 8-K: Press Release dated December 14, 2023](https://www.biopathholdings.com/wp-content/uploads/2023/12/Form_8-K_Press_Release-Completion_of_First_Dose_Cohort_of_Phase_1_1b_Clinical_Trial_of_BP1002.pdf)\n\n[December 8, 2023Schedule 14A: Proxy Supplement](https://www.biopathholdings.com/wp-content/uploads/2023/12/23-32444-1_Bio-Path-Holdings-Inc._DEFA14A-AsFiled.pdf)\n\n[December 8, 2023SEC Form 8-K: Amendment to Bylaws](https://www.biopathholdings.com/wp-content/uploads/2023/12/BPTH-Form-8-K-re-amendment-to-bylaws-as-filed.pdf)\n\n[November 15, 2023SEC Form 8-K: Press Release dated November 15, 2023](https://www.biopathholdings.com/wp-content/uploads/2023/11/BPTH_Form_8-K_Q3_Earnings_Release.pdf)\n\n[November 15, 2023SEC Form 10-Q for Period ending September 30, 2023](https://www.biopathholdings.com/wp-content/uploads/2023/11/BPTH_Form_10-Q_Q3_2023.pdf)\n\n[October 24, 2023SEC Form 8-K: Press Release dated October 24, 2023](https://www.biopathholdings.com/wp-content/uploads/2023/10/BPTH_Form_8-K_PR_10-24-2023.pdf)\n\n[September 15, 2023SEC Form 8-K: Nasdaq Notice of Noncompliance](https://www.biopathholdings.com/wp-content/uploads/2023/09/BPTH_Form-8-K_Nasdaq_Notice_of_Noncompliance.pdf)\n\n[August 16, 2023SEC Form 8-K: Second Quarter 2023 Earnings Release](https://www.biopathholdings.com/wp-content/uploads/2023/08/BPTH_Form_8-K_Q2-2023_Earnings_Release.pdf)\n\n[August 15, 2023SEC Form 10-Q for Period ending June 30, 2023](https://www.biopathholdings.com/wp-content/uploads/2023/08/BPTH_20230814_10-Q.pdf)\n\n[August 9, 2023SEC Form 8-K: Item 1.01 Entry Into a Material Definitive Agreement](https://www.biopathholdings.com/wp-content/uploads/2023/08/BPTH_8-K_20230809.pdf)\n\n[August 9, 2023SEC Form 424B3: Prospectus Supplement dated August 7, 2023](https://www.biopathholdings.com/wp-content/uploads/2023/08/BPTH_424B3_20230809.pdf)\n\n[August 9, 2023SEC Form 424B4: Prospectus](https://www.biopathholdings.com/wp-content/uploads/2023/08/BPTH_424B4_20230809.pdf)\n\n[August 2, 2023SEC Form S-1/A – Amendment No. 2](https://www.biopathholdings.com/wp-content/uploads/2023/08/Amendment_No_2_to_Form_S-1_20230802.pdf)\n\n[August 2, 2023SEC Form S-1/A – Amendment No. 1](https://www.biopathholdings.com/wp-content/uploads/2023/08/Amendment_No_1_to_Form_S-1_20230802.pdf)\n\n[August 2, 2023SEC Form 8-K: Press Release dated August 1, 2023](https://www.biopathholdings.com/wp-content/uploads/2023/08/BPTH_Form_8-K_Press_Release_08-01-2023.pdf)\n\n[July 18, 2023SEC Form 8-K: Press Release Dated July 17, 2023](https://www.biopathholdings.com/wp-content/uploads/2023/07/BPTH-Form_8-K-_Press_Release_7-17-2023.pdf)\n\n[May 12, 2023SEC Form 8-K: Press Release dated May 12, 2023](https://www.biopathholdings.com/wp-content/uploads/2023/05/BPTH_-8-K_2023-05-12.pdf)\n\n[May 12, 2023SEC Form 10-Q for quarterly period ended March 31, 2023](https://www.biopathholdings.com/wp-content/uploads/2023/05/BPTH_-Form_10-Q_Q1_2023.pdf)\n\n[March 31, 2023SEC Form 8-K: Press Release dated March 31, 2023](https://www.biopathholdings.com/wp-content/uploads/2023/03/BPTH_20230330_8-K.pdf)\n\n[March 31, 2023SEC Form 10-K for fiscal year ended December 31, 2022](https://www.biopathholdings.com/wp-content/uploads/2023/03/BPTH_20230330_10-K.pdf)\n\n[March 16, 2023SEC Form 8-K: Press Release dated March 16, 2023](https://www.biopathholdings.com/wp-content/uploads/2023/03/BPTH_Form_8-K_20230316.pdf)\n\n[December 29, 2022Delaying Amendment for Bio-Path Holdings, Inc.](https://www.biopathholdings.com/wp-content/uploads/2023/01/22-33714-1_Bio-Path-Holdings-Inc._DEL-AM-AsFiled.pdf)\n\n[December 29, 2022SEC Form S-1](https://www.biopathholdings.com/wp-content/uploads/2023/01/22-33298-1_Bio-Path-Holdings-Inc._S-1-AsFiled.pdf)\n\n[December 20, 2022SEC Form 8-K: Election of Directors; Appointment of Officers](https://www.biopathholdings.com/wp-content/uploads/2023/01/BPTH_8-K_20221220pdf.pdf)\n\n[December 9, 2022SEC Form 8-K: Termination of a Material Definitive Agreement](https://www.biopathholdings.com/wp-content/uploads/2022/12/BPTH_Form_8-K_ATM_Termination.pdf)\n\n[December 7, 2022SEC Form 8-K: Press Release dated December 7, 2022](https://www.biopathholdings.com/wp-content/uploads/2022/12/BPYJ_Form_8-K_12-07-2022.pdf)\n\n[November 15, 2022SEC Form 8-K: Press Release dated November 15, 2022](https://www.biopathholdings.com/wp-content/uploads/2022/11/BPTH_8K_20221115.pdf)\n\n[November 15, 2022SEC Form 10-Q for Period Ending September 30, 2022](https://www.biopathholdings.com/wp-content/uploads/2022/11/BPTH_Third_Qtr_10Q.pdf)\n\n[November 9, 2022SEC Form 8-K: Prospectus Supplement](https://www.biopathholdings.com/wp-content/uploads/2022/11/BPTH_8-K_20221109.pdf)\n\n[November 9, 2022SEC Form 424B5: Prospectus Supplement](https://www.biopathholdings.com/wp-content/uploads/2022/11/BPTH_424B5_20221109.pdf)\n\n[October 28, 2022SEC Schedule 14A: Proxy Statement](https://www.biopathholdings.com/wp-content/uploads/2022/10/BPTH-DEF14A_10-28-2022.pdf)\n\n[October 28, 2022SEC Schedule 14A: Information Required In Proxy Statement](https://www.biopathholdings.com/wp-content/uploads/2022/10/BPTH-DEFA14A_10-28-2022.pdf)\n\n[October 24, 2022SEC Form 8-K: Press Release dated October 24, 2022](https://www.biopathholdings.com/wp-content/uploads/2022/10/BPTH_8K_20221024.pdf)\n\n[September 6, 2022SEC Form 8-K: Press Release dated September 6, 2022](https://www.biopathholdings.com/wp-content/uploads/2022/09/BPTH_Form_8-K_PRelease_09-06-2022.pdf)\n\n[August 16, 2022SEC Form 8-K: Press Release dated August 16, 2022](https://www.biopathholdings.com/wp-content/uploads/2022/08/BPTH_Form_8-K_Q2-2022-Earnings-Release.pdf)\n\n[August 16, 2022SEC Form 10-Q for Period Ending June 30, 2022](https://www.biopathholdings.com/wp-content/uploads/2022/08/BPTH_20220815_10-Q-Q2_2022.pdf)\n\n[July 29, 2022SEC Form 424B5: Prospectus Supplement](https://www.biopathholdings.com/wp-content/uploads/2022/07/BPTH_424B5_20220728.pdf)\n\n[June 16, 2022SEC Form 424B5: Prospectus](https://www.biopathholdings.com/wp-content/uploads/2022/06/BPTH_424B5_1_20220616.pdf)\n\n[June 16, 2022SEC Form 424B5: Prospectus](https://www.biopathholdings.com/wp-content/uploads/2022/06/BPTH_424B5_2_20220616.pdf)\n\n[June 3, 2022SEC Form S-3: Prospectus](https://www.biopathholdings.com/wp-content/uploads/2022/06/BPTH_S-3_20220603.pdf)\n\n[May 17, 2022SEC Form 8-K: Results of Operations and Financial Condition](https://www.biopathholdings.com/wp-content/uploads/2022/05/BPTH_20220517_8-K.pdf)\n\n[May 17, 2022SEC Form 10-Q: For Period Ending March 31, 2022](https://www.biopathholdings.com/wp-content/uploads/2022/05/BPTH_8-K_20220516_10-Q.pdf)\n\n[April 12, 2022SEC Form 8-K: Press Release Dated April 12, 2022](https://www.biopathholdings.com/wp-content/uploads/2022/04/BPTH_8-K_20220412.pdf)\n\n[April 6, 2022SEC Form 8-K: Change in Directors](https://www.biopathholdings.com/wp-content/uploads/2022/04/BPTH_Form_8-K_2022_04_06.pdf)\n\n[March 11, 2022SEC Form 8-K: Press Release Dated March 11, 2022](https://www.biopathholdings.com/wp-content/uploads/2022/03/BPTH_20220311_8-K.pdf)\n\n[March 11, 2022SEC Form 10-K: For Fiscal Period Ending December 31, 2021](https://www.biopathholdings.com/wp-content/uploads/2022/03/BPTH_20220310_10-Kb.pdf)\n\n[March 9, 2022SEC Form 8-K: Press Release Dated March 8, 2022](https://www.biopathholdings.com/wp-content/uploads/2022/03/BPTH_20220309_8-K.pdf)\n\n[February 25, 2022SEC Form 8-K: Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard](https://www.biopathholdings.com/wp-content/uploads/2022/02/BPTH_8-K_20220225.pdf)\n\n[February 18, 2022SEC Form 8-K: Departure of Directors or Certain Officers](https://www.biopathholdings.com/wp-content/uploads/2022/02/BPTH_8-K_20220218.pdf)\n\n[January 5, 2022SEC Form 8-K: Press Release Dated January 5, 2021](https://www.biopathholdings.com/wp-content/uploads/2022/01/BPTH_20220105_8-K.pdf)\n\n[December 29, 2021SEC Form 8-K: Submission of Matters to a Vote of Security Holders](/wp-content/uploads/2021/12/BPTH_20211229_8-K.pdf)\n\n[December 17, 2021SEC Form 8-K: Item 8.01 Other Events](/wp-content/uploads/2021/12/BPTH_8-K_20211217.pdf)\n\n[December 13, 2021SEC Form 8-K: Press Release Dated December 13, 2021](/wp-content/uploads/2021/12/BPTH_Form-8-K_121320211.pdf)\n\n[November 12, 2021SEC Form 8-K: Press Release Dated November 12, 2021](/wp-content/uploads/2021/12/BPTH_20211112_8-K.pdf)\n\n[November 10, 2021SEC Form 10-Q for period ending September 30, 2021](/wp-content/uploads/2021/12/BPTH_20211110_10-Q-Q3_2021.pdf)\n\n[November 4, 2021SEC Form Schedule 14A: Proxy Materials](/wp-content/uploads/2021/12/BPTH_20211104_DEFA14A_Proxy_Materials.pdf)\n\n[November 4, 2021SEC Form Schedule 14A: Notice of Annual Meeting](/wp-content/uploads/2021/12/BPTH_20211104_DEF-14A_Annual_Meeting.pdf)\n\n[November 4, 2021SEC Form 8-K: Press Release Dated November 4, 2021](/wp-content/uploads/2021/12/BPTH_20211104_8-K.pdf)\n\n[October 27, 2021SEC Form 8K: Press Release Dated October 27, 2021](/wp-content/uploads/2021/12/BPTH_8-K_20211027.pdf)\n\n[August 24, 2021SEC Form 8-K: Press Release dated August 24, 2021](/wp-content/uploads/2021/08/BPTH_08242021_8-K.pdf)\n\n[August 19, 2021SEC Form 424B5: PROSPECTUS SUPPLEMENT (To Prospectus dated June 5, 2019)](/wp-content/uploads/2021/08/BPTH_08192021_424B5.pdf)\n\n[August 19, 2021SEC Form 8-K: Items 8.01 & 9.01](/wp-content/uploads/2021/08/BPTH_08192021_8-K.pdf)\n\n[August 13, 2021SEC Form 8K: Press Release Dated August 13, 2021](/wp-content/uploads/2021/08/BPTH_08132021_8-K.pdf)\n\n[August 13, 2021SEC Form 10-Q for period ending June 30, 2021](/wp-content/uploads/2021/08/BPTH_08122021_10-Q.pdf)\n\n[June 23, 2021SEC Form 8K: Press Release Dated June 22, 2021](/wp-content/uploads/2021/06/BPTH_8-K_20210622.pdf)\n\n[May 14, 2021SEC Form 8K: Press Release Dated May 14, 2021](/wp-content/uploads/2021/05/BPTH_8-K_20210514.pdf)\n\n[May 14, 2021SEC Form 10-Q for period ending March 31, 2021](/wp-content/uploads/2021/05/BPTH_10-Q_20210514.pdf)\n\n[May 14, 2021Interactive Data 10-Q](/wp-content/uploads/2021/05/XBRL_files_20210514.zip)\n\n[April 23, 2021SEC Form 8K: Press Release Dated April 22, 2021](/wp-content/uploads/2021/04/BPTH_8-K_20210423.pdf)\n\n[April 14, 2021SEC Form 8K: Press Release Dated April 12, 2021](/wp-content/uploads/2021/04/BPTH_8-K_20210414.pdf)\n\n[April 6, 2021SEC Form 8K: Press Release Dated April 6, 2021](/wp-content/uploads/2021/04/BPTH_8-K_20210405.pdf)\n\n[March 11, 2021SEC Form 8K: Press Release Dated March 11, 2021](/wp-content/uploads/2021/03/BPTH_8-K_20210311.pdf)\n\n[March 10, 2021SEC Form 8K: Press Release Dated March 10, 2021](/wp-content/uploads/2021/03/BPTH_8-K_20210310.pdf)\n\n[March 10, 2021SEC Form 10-K for Fiscal Year Ended December 31, 2020](/wp-content/uploads/2021/03/BPTH_10-K_2020.pdf)\n\n[March 10, 2021Interactive Data 10-K](/wp-content/uploads/2021/03/20210310XBRL-files.zip)\n\n[February 17, 2021SEC Form 424B5: Prospectus Supplement (To Prospectus Dated June 5, 2019)](/wp-content/uploads/2021/02/Form_424B5_20210217.pdf)\n\n[February 17, 2021SEC Form 8K: Entry Into a Material Definitive Agreement and Press Release dated February 16, 2021](/wp-content/uploads/2021/02/BPTH_8-K20210217.pdf)\n\n[February 11, 2021SEC Form 8K: Press Release Dated February 10, 2021](/wp-content/uploads/2021/02/BPTH_8-K_20210210.pdf)\n\n[December 18, 2020SEC Form 8K: Press Release Dated December 18, 2020: Submission of Matters to a Vote of Security Holders](/wp-content/uploads/2020/12/BPTH_8-K_20201218.pdf)\n\n[November 20, 2020SEC Form 8K: Press Release Dated November 19, 2020](/wp-content/uploads/2020/11/BPTH_8-K_20201119.pdf)\n\n[November 13, 2020SEC Form 8K: Press Release Dated November 13, 2020](/wp-content/uploads/2020/11/BPTH_8-K_20201113.pdf)\n\n[November 13, 2020SEC Form 10-Q for period ending September 30, 2020](/wp-content/uploads/2020/11/BPTH_10-Q_20200930.pdf)\n\n[November 13, 2020Interactive Data Files](/wp-content/uploads/2020/11/20200930_XBRLfiles.zip)\n\n[November 5, 2020Proxy Notice Card](/wp-content/uploads/2020/11/BPTH-2020-Proxy-Notice-Card.pdf)\n\n[November 5, 2020Proxy Statement](/wp-content/uploads/2020/11/BPTH-2020-Proxy-Statement.pdf)\n\n[November 5, 2020Annual Report 2019](/wp-content/uploads/2020/11/BPTH-Annual-Report-2019.pdf)\n\n[October 22, 2020SEC Form 8K: Press Release Dated October 22, 2020](/wp-content/uploads/2020/10/BPTH_8-K_20201022.pdf)\n\n[September 10, 2020SEC Form 8-K: Press Release Dated September 9, 2020](/wp-content/uploads/2020/09/BPTH_8-K20200910.pdf)\n\n[August 14, 2020SEC Form 8-K: Press Release Dated August 14, 2020](/wp-content/uploads/2020/08/BPTH_8_K_PR_20200814.pdf)\n\n[August 14, 2020SEC Form 10-Q for period ending June 30, 2020](/wp-content/uploads/2020/08/BPTH_10_Q_Draft7_20200814.pdf)\n\n[August 14, 2020Interactive Data Files](/wp-content/uploads/2020/08/BPTH_XBRL_files_06302020_10Q.zip)\n\n[August 14, 2020SEC Form 8-K: Press Release Dated August 13, 2020](/wp-content/uploads/2020/08/BPTH_8-K_Press_Release.pdf)\n\n[July 14, 2020SEC 424B5: Prospectus Supplement (To Prospectus Dated June 5, 2019)](/wp-content/uploads/2020/07/BPTH_424B5_20200714.pdf)\n\n[July 14, 2020SEC Form 8-K: Entry into a Material Agreement](/wp-content/uploads/2020/07/BPTH_8-K_20200714.pdf)\n\n[July 7, 2020SEC Form 8-K: July 6, 2020: Termination of a Material Definitive Agreement](/wp-content/uploads/2020/07/BPTH_8-K_20200706.pdf)\n\n[May 29, 2020SEC Form 8-K: Press Release Dated May 29, 2020](/wp-content/uploads/2020/05/BPTH_8-K_20200529.pdf)\n\n[May 15, 2020SEC Form 8-K: Press Release Dated May 15, 2020](/wp-content/uploads/2020/05/BPTH_8-K_20200515.pdf)\n\n[May 15, 2020SEC Form 10-Q for period ending March 31, 2020](/wp-content/uploads/2020/05/BPTH_10-Q_2020_03_31.pdf)\n\n[May 15, 2020Interactive Data Files](/wp-content/uploads/2020/05/BPTH_10-Q1_XBRL.zip)\n\n[May 14, 2020SEC Form 8-K: Press Release Dated May 13, 2020](/wp-content/uploads/2020/05/BPTH_8-K_20200514.pdf)\n\n[April 27, 2020SEC Form 8-K: Press Release Dated April 27, 2020](/wp-content/uploads/2020/04/BPTH_8-K_2020427.pdf)\n\n[April 14, 2020SEC Form 8-K: Press Release Dated April 13, 2020](/wp-content/uploads/2020/04/BPTH_8-K_20200414.pdf)\n\n[March 11, 2020SEC Form 8-K: Changes in Registrant’s Certifying Accountant](/wp-content/uploads/2020/03/BPTH_8-K_20200310.pdf)\n\n[March 6, 2020SEC Form 8-K: Press Release Dated March 6, 2020](/wp-content/uploads/2020/03/BPTH_8-K_20200306.pdf)\n\n[March 5, 2020SEC Form 10-K for Fiscal Year Ended December 31, 2019](/wp-content/uploads/2020/03/bpth_10-K_20200306.pdf)\n\n[March 5, 2020Interactive Data 10-K](/wp-content/uploads/2020/03/bpth-20191231_XBRL.zip)\n\n[February 14, 2020Schedule 13G/A](/wp-content/uploads/2020/03/bpth_Sched_13GA_20200214-2.pdf)\n\n[February 14, 2020Schedule 13G/A](/wp-content/uploads/2020/03/bpth_Sched_13GA_20200214-1.pdf)\n\n[February 10, 2020Schedule 13G/A](/wp-content/uploads/2020/03/bpth_Sched_13GA_20200210.pdf)\n\n[January 15, 2020Schedule 13G/A](/wp-content/uploads/2020/03/bpth_Sched_13A_20200115.pdf)\n\n[January 8, 2020SEC Form 8-K: Press Release Dated January 8, 2020](/wp-content/uploads/2020/01/BPTH_8-K_20200108.pdf)\n\n[December 23, 2019SEC Form 8-K: Submission of Matters to a Vote of Security Holders](/wp-content/uploads/2019/12/BPTH_8-K_20191223.pdf)\n\n[December 2, 2019Schedule 13G](/wp-content/uploads/2020/03/bpth_Sched_13G_20191202-2.pdf)\n\n[December 2, 2019Schedule 13G](/wp-content/uploads/2020/03/bpth_Sched_13G_20191202.pdf)\n\n[November 27, 2019Schedule 13G](/wp-content/uploads/2020/03/bpth_Sched_13_20191127.pdf)\n\n[November 26, 2019SEC Form 8-K: Press Release Dated November 26, 2019](/wp-content/uploads/2019/11/BPTH_8-K_20191126.pdf)\n\n[November 25, 2019SEC 424B5 Prospectus Supplement (To Prospectus Dated June 5, 2019)](/wp-content/uploads/2019/11/BPTH_424B5_20191121.pdf)\n\n[November 25, 2019SEC Form 8-K: Entry Into a Material Agreement](/wp-content/uploads/2019/11/BPTH_8-K_Matl_lAgreement.pdf)\n\n[November 21, 2019SEC Form 8-K: Press Release Dated November 21, 2019](/wp-content/uploads/2019/11/BPTH_8-K_20191121.pdf)\n\n[November 15, 2019SEC Form 8-K: Press Release Dated November 15, 2019](/wp-content/uploads/2019/11/BPTH_8-K_20191115.pdf)\n\n[November 15, 2019SEC FORM 10-Q for Period Ending September 30, 2019](/wp-content/uploads/2019/11/BPTH_10-Q_2019_11_15.pdf)\n\n[November 15, 2019Interactive Data Files for 10-Q For Period Ending September 30, 2019](/wp-content/uploads/2019/11/XBRLfiles20191115.zip)\n\n[November 4, 2019Proxy Notice Card](/wp-content/uploads/2019/11/BPTH._DEFA14A.pdf)\n\n[November 4, 2019Proxy Statement](/wp-content/uploads/2019/11/BPTH_DEF-14.pdf)\n\n[November 4, 2019Annual Report 2018](/wp-content/uploads/2019/11/BPTH_PRINT-Annual_Report_2018.pdf)\n\n[October 15, 2019SEC Form 8-K: Press Release Dated October 15, 2019](/wp-content/uploads/2019/10/BPTH_8-K_20191015.pdf)\n\n[September 26, 2019SEC Form 8-K: Press Release Dated September 25, 2019](/wp-content/uploads/2019/09/BPTH_8-K_20190925.pdf)\n\n[September 4, 2019SEC Form 8-K: Press Release Dated September 3, 2019](/wp-content/uploads/2019/09/BPTH_8-K_20190904.pdf)\n\n[August 27, 2019SEC Form 8-K: Press Release Dated August 26, 2019](/wp-content/uploads/2019/08/BPTH_8-K_20190827.pdf)\n\n[August 15, 2019SEC Form 8-K: Press Release Dated August 15, 2019](/wp-content/uploads/2019/08/BPTH_8-K_20190815.pdf)\n\n[August 15, 2019SEC Form 10-Q: For Period Ended June 30, 2019](/wp-content/uploads/2019/08/BPTH_10-Q_20190630.pdf)\n\n[August 15, 2019Interactive Data Files (XBRL)](/wp-content/uploads/2019/08/BPTH_10-Q_20190630_XBRL_files.zip)\n\n[June 4, 2019SEC Form 8-K: First Amendment to Lease Agreement](/wp-content/uploads/2019/06/BPTH_8-K_20190604.pdf)\n\n[May 16, 2019SEC Form S-3](/wp-content/uploads/2019/05/BPTH_S-3_20190516.pdf)\n\n[May 16, 2019SEC Form 8-K: Press Release Dated May 16, 2019](/wp-content/uploads/2019/05/BPTH_8-K_20190516.pdf)\n\n[May 15, 2019SEC Form 10-Q: For Period Ended March 31, 2019](/wp-content/uploads/2019/05/BPTH_10-Q_20190515.pdf)\n\n[April 12, 2019SEC Form for Withdrawl of Registration Statement on Form S-1](/wp-content/uploads/2019/04/S1_withdrawal_2019-0412.pdf)\n\n[April 4, 2019SEC Form 8-K: Press Release Dated April 3, 2019](/wp-content/uploads/2019/04/BPTH_8_K_20190404.pdf)\n\n[March 20, 2019SEC Form 8-K: Press Release Dated March 20, 2019](/wp-content/uploads/2019/03/BPTH_8-K_20190320.pdf)\n\n[March 19, 2019SEC Form 10-K for Period Ended December 31, 2018](/wp-content/uploads/2019/03/BPTH_10-K_20190319.pdf)\n\n[March 19, 2019Interactive Data Files (XBRL)](/wp-content/uploads/2019/03/XBRL_20181231.zip)\n\n[March 19, 2019SEC Form S-1/A](/wp-content/uploads/2019/03/BPTH_S-1A_20190319.pdf)\n\n[March 18, 2019SEC Form D: Notice of Exempt Offering of Securities](/wp-content/uploads/2019/03/BPTH-_Form_D_2019031.pdf)\n\n[March 14, 2019SEC Form 8-K: Entry Into a Material Agreement](/wp-content/uploads/2019/03/BPTH_8_K20190313MtlAgrmt.pdf)\n\n[March 14, 2019SEC 424B5 Prospectus Supplement (To Prospectus Dated January 9, 2017)](/wp-content/uploads/2019/03/BPTH_ProspectusSup_20190313.pdf)\n\n[March 6, 2019SEC Form 8-K: Press Release Dated March 6, 2019](/wp-content/uploads/2019/03/BPTH_8-K_20190306.pdf)\n\n[February 28, 2019SEC Form 8-K: Press Release Dated February 28, 2019](/wp-content/uploads/2019/02/BPTH_8-K_20190228.pdf)\n\n[February 5, 2019Nasdaq notifying Bio-Path that it has regained compliance for continued listing on The Nasdaq Capital Market](/wp-content/uploads/2019/02/BPTH_8k-_20190205.pdf)\n\n[January 25, 2019SEC Form D](/wp-content/uploads/2019/01/BPTH_Form_D_2019_RDO.pdf)\n\n[January 25, 2019SEC Form D](/wp-content/uploads/2019/01/BPTH_Form_D_2019_Underwritten_Takedown.pdf)\n\n[January 22, 2019SEC Form 8-K: Entry Into a Material Agreement](/wp-content/uploads/2019/01/BPTH_8-K_20190122.pdf)\n\n[January 22, 2019PROSPECTUS SUPPLEMENT (To Prospectus dated January 9, 2017)](/wp-content/uploads/2019/01/BPTH_424B5_20190122.pdf)\n\n[January 16, 2019SEC Form 8-K: Entry Into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws, Press Release dated January 14, 2019](/wp-content/uploads/2019/01/BPTH_8K_20190116.pdf)\n\n[January 16, 2019PROSPECTUS SUPPLEMENT (To Prospectus dated January 9, 2017)](/wp-content/uploads/2019/01/BPTH_424B5_20190116.pdf)\n\n[January 14, 2019SEC 424B5 Preliminary Prospectus Supplement (To Prospectus Dated January 9, 2017)](/wp-content/uploads/2019/01/BPTH_424B5_20190114.pdf)\n\n[December 28, 2018SEC Form S-1](/wp-content/uploads/2019/01/SEC-Form_S-1_20181228-2.pdf)\n\n[December 28, 2018SEC Form S-1](/wp-content/uploads/2019/01/SEC-Form_S-1_20181228.pdf)\n\n[December 28, 2018SEC Form 8-K: Press Release Dated December 27, 2018](/wp-content/uploads/2019/01/BPTH_8-K_20181228.pdf)\n\n[December 22, 2018SEC Form 8-K: Submission of Matters to a Vote of Security Holders](/wp-content/uploads/2018/12/BPTH_8-K_20181221.pdf)\n\n[December 4, 2018SEC Form 8-K: Press Release Dated December 3, 2018](/wp-content/uploads/2018/12/BPTH_8K_20181203.pdf)\n\n[November 16, 2018SEC Form 8-K: Press Release Dated November 15, 2018](/wp-content/uploads/2018/11/BPTH_8-K_20181115.pdf)\n\n[November 15, 2018SEC Form 10-Q: For Period Ended September 30, 2018](/wp-content/uploads/2018/11/BPTH_10-Q_20181115-1.pdf)\n\n[November 2, 2018Definitive Proxy Statement – Schedule 14A](/wp-content/uploads/2018/11/BPTH_DEF_14A_2018.pdf)\n\n[November 2, 20182017 Annual Report](/wp-content/uploads/2018/11/BPTH_Annual_Report_2017.pdf)\n\n[November 2, 2018SEC Form 8-K: Press Release Dated November 1, 2018](/wp-content/uploads/2018/11/BPTH_8-K_20181102.pdf)\n\n[October 23, 2018SEC Schedule 14A: Pre Proxy Statement – NOTICE OF ANNUAL MEETING OF STOCKHOLDERS](/wp-content/uploads/2018/10/BPTH_PRE-14.pdf)\n\n[October 5, 2018SEC Form D: Notice of Exempt Offering of Securities](/wp-content/uploads/2018/10/BPTH-_Form_D_20181005_Private_Placement_4832.pdf)\n\n[September 21, 2018SEC 424B5 Prospectus Supplement (To Prospectus Dated January 9, 2017)](/wp-content/uploads/2018/09/BPTH_424B5_20180921.pdf)\n\n[September 21, 2018SEC Form 8-K: Entry Into a Material Definitive Agreement](/wp-content/uploads/2018/09/BPTH_8-K_20180921.pdf)\n\n[August 29, 2018SEC Form 8-K: Press Release Dated August 29, 2018](/wp-content/uploads/2018/08/BPTH_8K_20180829.pdf)\n\n[August 28, 2018SEC Form 8-K: Press Release Dated August 27 2018](/wp-content/uploads/2018/08/BPTH_8-K_20180828.pdf)\n\n[August 16, 2018SEC Form 8-K: Press Release Dated August 16, 2018](/wp-content/uploads/2018/08/bpth_8-K_20180816.pdf)\n\n[August 15, 2018SEC Form 8-K: Press Release Dated August 15, 2018](/wp-content/uploads/2018/08/BPTH_8-K_20180815.pdf)\n\n[August 15, 2018SEC Form 10-Q: For Period Ended June 30, 2018](/wp-content/uploads/2018/08/BPTH_10-Q_2Q2018.pdf)\n\n[August 15, 2018Interactive Data Files (XBRL) for 10-Q for Period Ended June 30, 2018](/wp-content/uploads/2018/08/bpth-20180630.zip)\n\n[May 16, 2018SEC Form 10-Q: For Period Ended March 31, 2018](/wp-content/uploads/2018/05/BPTH_10Q_20180516.pdf)\n\n[May 16, 2018Interactive Data Files (XBRL) for 10-Q for Period Ended March 31, 2018](/wp-content/uploads/2018/05/bpth-20180331.zip)\n\n[May 16, 2018SEC Form 8-K: Press Release Dated May 16, 2018](/wp-content/uploads/2018/05/BPTH_8K_20180516.pdf)\n\n[May 10, 2018SEC Form 8-K: Press Release Dated May 10, 2018](/wp-content/uploads/2018/05/BPTH_8K_20180510.pdf)\n\n[April 19, 2018SEC Form 8-K: Press Release Dated April 18, 2018](/wp-content/uploads/2018/04/BPTH_8-K_20180419.pdf)\n\n[April 5, 2018SEC Form 8-K: Press Release Dated April 3, 2018](/wp-content/uploads/2018/04/BPTH_8K_20180404.pdf)\n\n[April 3, 2018SEC Form 8-K: Bio-Path Holdings Reports Full Year 2017 Financial Results / Press Release Dated April 3, 2018](/wp-content/uploads/2018/04/BPTH_8K_20180403.pdf)\n\n[April 2, 2018SEC Form 10-K: For the fiscal year ended December 31, 2017](/wp-content/uploads/2018/04/BPTH_10_K_2017.pdf)\n\n[April 2, 2018Interactive Data Files (XBRL) for 10-K for Fiscal Year Ended December 31, 2017](/wp-content/uploads/2018/04/bpth_20171231.zip)\n\n[March 29, 2018SEC Form 8-K: Press Release Dated March 29, 2018](/wp-content/uploads/2018/03/BPTH_8K_20180329.pdf)\n\n[March 15, 2018SEC Form 8-K: Press Release Dated March 15, 2018](/wp-content/uploads/2018/03/BPTH_8K_20180315.pdf)\n\n[March 7, 2018SEC Form 8-K: Press Release Dated March 6, 2018](/wp-content/uploads/2018/03/BPTH_8K_20180306.pdf)\n\n[February 26, 2018SEC Form 8-K: In Compliance Nasdaq](/wp-content/uploads/2018/02/BPTH_8K_InCompliance.pdf)\n\n[February 21, 2018SEC Form S8](/wp-content/uploads/2018/08/BPTH_S8.pdf)\n\n[February 9, 2018SEC Form 8-K: Certificate of Amendment to Certificate of Incorporation, Press Releases Date February 5 & February 9, 2018](/wp-content/uploads/2018/02/BPTH_8K_20180209.pdf)\n\n[February 5, 2018SEC Form 8-K: Press Release Dated February 5, 2018](/wp-content/uploads/2018/02/BPTH_8K_20180205.pdf)\n\n[January 2, 2018SEC Form 8-K: Press Release Dated December 29, 2017](/wp-content/uploads/2018/01/BPTH_8K_20180102.pdf)\n\n[December 28, 2017SEC Form 8-K: Submission of Matters to a Vote of Security Holders](/wp-content/uploads/2017/12/BPTH_8K_20171227.pdf)\n\n[November 16, 2017SEC Form S3 – Registration Statement](/wp-content/uploads/2017/11/BPTH_S3_20171116.pdf)\n\n[November 9, 2017SEC Form 10-Q: For the quarterly period ended September 30, 2017](/wp-content/uploads/2017/11/BPTH_10Q_20171109.pdf)\n\n[November 9, 2017Interactive Data Files (XBRL) for 10-Q: Period Ending September 30, 2017](/wp-content/uploads/2017/11/BPTH_10Q_xbrl_20171109.zip)\n\n[November 9, 2017SEC Form 8-K: Press Release Dated November 9, 2017](/wp-content/uploads/2017/11/BPTH_8K_20171109.pdf)\n\n[November 7, 2017SEC Form 8-K: Press Release Dated November 6, 2017](/wp-content/uploads/2017/11/BPTH_8K_20171107.pdf)\n\n[November 6, 2017SEC Form 8-K: Entry Into a Material Definitive Agreement](/wp-content/uploads/2017/11/BPTH_8-K_20171106.pdf)\n\n[November 6, 2017SEC 424B5: Prospectus Supplement](/wp-content/uploads/2017/11/BPTH_ProspectusSupplement_20171106.pdf)\n\n[November 3, 20172016 Annual Report](/wp-content/uploads/2017/11/BPTH_2016_Annual_Report.pdf)\n\n[November 3, 2017Definitive Proxy Statement – Schedule 14A](/wp-content/uploads/2017/11/BPTH._DEF-14A_Proxy.pdf)\n\n[October 25, 2017SEC Schedule 14A – Preliminary Proxy Statement](/wp-content/uploads/2017/10/BPTH_2017_14A_Pre_Proxy.pdf)\n\n[September 6, 2017SEC Form 8-K: Press Release Dated September 5, 2017](/wp-content/uploads/2017/09/BPTH_8K_20170906.pdf)\n\n[September 1, 2017SEC Form 8-K: Nasdaq Grants Additional 180 Calendar Days to Regain Compliance](/wp-content/uploads/2017/09/BPTH_8-K_20170901.pdf)\n\n[August 16, 2017SEC Form 8-K: Departure of Directors or Certain Officers / Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard](/wp-content/uploads/2017/08/BPTH_8-K_20170816.pdf)\n\n[August 10, 2017SEC Form 8-K: Press Release Dated August 10, 2017](/wp-content/uploads/2017/08/BPTH_8-K_20170810.pdf)\n\n[August 9, 2017SEC Form 10-Q: For the quarterly period ended June 30, 2017](/wp-content/uploads/2017/08/BPTH_10Q_20170809.pdf)\n\n[August 9, 2017Interactive Data Files (XBRL) for 10-Q: Period Ending June 30, 2017](/wp-content/uploads/2017/08/bpth_20170630.zip)\n\n[July 20, 2017SEC Form 8-K: Stockholder Letter Dated July 19, 2017](/wp-content/uploads/2017/07/BPTH_8-K_20170720.pdf)\n\n[July 18, 2017SEC Form 8-K: Press Release Dated July 17, 2017](/wp-content/uploads/2017/07/BPTH_8K_20170718.pdf)\n\n[July 17, 2017SEC FORM 4 – Statement of Changes in Beneficial Ownership of Securities](/wp-content/uploads/2017/08/SEC-FORM-4-2017-07-17.pdf)\n\n[July 17, 2017SEC FORM 3 – Initial Statement of Beneficial Ownership of Securities](/wp-content/uploads/2017/08/SEC-FORM-3-2017-07-17.pdf)\n\n[June 20, 2017SEC Form 8-K: Stockholder Letter Dated June 20, 2017](/wp-content/uploads/2017/06/BPTH_8-K_Sh_Letter.pdf)\n\n[June 19, 2017SEC Form 8-K: Entry into a Material Definitive Agreement / Form of Warrant Amendment](/wp-content/uploads/2017/06/BPTH_8K_20170619.pdf)\n\n[June 7, 2017SEC Form 8-K: First Amended and Restated Bylaws](/wp-content/uploads/2017/06/BPTH_8K_AmndByLaws.pdf)\n\n[May 22, 2017SEC Form 8-K: Entry into a Material Definitive Agreement.](/wp-content/uploads/2017/05/BPTH_8K_20170522.pdf)\n\n[May 11, 2017SEC Form 8-K: Press Release Dated May 11, 2017](/wp-content/uploads/2017/05/BPTH_8-K_20170511.pdf)\n\n[May 11, 2017SEC Form 10-Q: For the quarterly period ended March 31, 2017](/wp-content/uploads/2017/05/BPTH_10-Q_20170510.pdf)\n\n[May 11, 2017Interactive Data Files (XBRL) for 10-Q: Period Ending March 31, 2017](/wp-content/uploads/2017/05/bpth-20170331.zip)\n\n[May 2, 2017SEC FORM 4 – Statement of Changes in Beneficial Ownership of Securities](/wp-content/uploads/2017/08/SEC-FORM-4-2017-05-02.pdf)\n\n[April 17, 2017SEC Form 8-K: Press Release Dated April 17, 2017](/wp-content/uploads/2017/04/BPTH_8-K_20170417.pdf)\n\n[April 5, 2017SEC Form 8-K: Press Release Dated April 5, 2017](/wp-content/uploads/2017/04/BPTH_8K_20170405.pdf)\n\n[March 27, 2017SEC FORM 4 – Statement of Changes in Beneficial Ownership of Securities](/wp-content/uploads/2017/08/SEC-FORM-4-2017-03-27MG.pdf)\n\n[March 27, 2017SEC FORM 4 – Statement of Changes in Beneficial Ownership of Securities](/wp-content/uploads/2017/08/SEC-FORM-4-2017-03-27CH.pdf)\n\n[March 27, 2017SEC FORM 4 – Statement of Changes in Beneficial Ownership of Securities](/wp-content/uploads/2017/08/SEC-FORM-4-2017-03-27DM.pdf)\n\n[March 27, 2017SEC FORM 4 – Statement of Changes in Beneficial Ownership of Securities](/wp-content/uploads/2017/08/SEC-FORM-4-2017-03-27AS.pdf)\n\n[March 27, 2017SEC FORM 4 – Statement of Changes in Beneficial Ownership of Securities](/wp-content/uploads/2017/08/SEC-FORM-4-2017-03-27UM.pdf)\n\n[March 15, 2017SEC Form 10-K: For the fiscal year ended December 31, 2016](/wp-content/uploads/2017/03/BPTH_10K_20170315.pdf)\n\n[March 15, 2017Interactive Data Files (XBRL) for 10-K for Fiscal Year Ended December 31, 2016](/wp-content/uploads/2017/03/bpth-20161231.zip)\n\n[March 15, 2017SEC Form 8-K: Press Releases Dated March 14 & March 15, 2017](/wp-content/uploads/2017/03/BPTH_8K_20170315.pdf)\n\n[March 10, 2017SEC Form 8-K: Press Release Dated March 10, 2017](/wp-content/uploads/2017/03/BPTH_8K_20170310.pdf)\n\n[March 8, 2017SEC Form 8-K: Failure to Satisfy a Continued Listing Rule or Standard](/wp-content/uploads/2017/03/BPTH_8-K_20170308.pdf)\n\n[February 22, 2017SEC Form 8-K: Press Release Dated February 21, 2017](/wp-content/uploads/2017/02/BPTH_8-K_20170221.pdf)\n\n[February 8, 2017SEC Form 8-K: Press Release Dated February 7, 2017](/wp-content/uploads/2017/02/BPTH_8K_20170207.pdf)\n\n[January 11, 2017SEC 424B5 – Prospectus – Up to 5,441.176 Shares of Common Stock](/wp-content/uploads/2017/01/Prospectus_5441_Shares_Common_Stock.pdf)\n\n[January 10, 2017SEC 424B5 – Prospectus – Up to $25,000,000 of Common Stock](/wp-content/uploads/2017/01/Prospectus_Common_Stock.pdf)\n\n[December 21, 2016SEC Form S3 – Registration Statement](/wp-content/uploads/2016/12/BPTH_S-3_20161221.pdf)\n\n[December 16, 2016SEC Form 8-K: Submission of Matters to a Vote of Security Holders. / Slide Presentation dated December 2016](/wp-content/uploads/2016/12/BPTH_8K_20161216.pdf)\n\n[December 6, 2016SEC Form 8-K: Press Release Dated December 5, 2016](/wp-content/uploads/2016/12/BPTH_8-K_20161206.pdf)\n\n[November 10, 2016SEC FORM 8-K – for Press Release Dated November 10, 2016](/wp-content/uploads/2016/11/BPTH_8_K_20161110.pdf)\n\n[November 10, 2016SEC FORM 10-Q – For Period Ending September 30, 2016](/wp-content/uploads/2016/11/BPTH_10_Q_20161109.pdf)\n\n[November 10, 2016Interactive Data for 10-Q Period Ending September 30, 2016]()\n\n[November 4, 2016SEC Form 8-K: Press Releases Dated November 2, 3, & 4, 2016](/wp-content/uploads/2016/11/BPTH_8K_20161104.pdf)\n\n[October 28, 2016Schedule 14A – Definitive Additional Materials](/wp-content/uploads/2016/10/BPTH_DEFA14A_20161028.pdf)\n\n[October 28, 2016Schedule 14A – Definitive Proxy Statement](/wp-content/uploads/2016/10/BPTH_DEF_14A_20161028.pdf)\n\n[October 28, 2016Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2015](/wp-content/uploads/2016/10/BPTH_2015_AnnualReport.pdf)\n\n[September 8, 2016SEC Form 8-K: Press Release Dated September 6, 2016](/wp-content/uploads/2016/09/BPTH_8K_20160907.pdf)\n\n[August 10, 2016SEC FORM 8-K – for Press Release Dated August 10, 2016](/wp-content/uploads/2016/08/bpth_8-K_20160810.pdf)\n\n[August 10, 2016SEC FORM 10-Q – For Period Ending June 30, 2016](/wp-content/uploads/2016/08/BPTH_10-Q_20160810.pdf)\n\n[August 10, 2016Interactive Data Files for 10-Q](https://www.sec.gov/cgi-bin/viewer?action=view&cik=1133818&accession_number=0001144204-16-117698&xbrl_type=v)\n\n[August 2, 2016SEC Form 8-K](/wp-content/uploads/2016/08/bpth_8K_20160801.pdf)\n\n[July 6, 2016SEC Form 8-K: Press Release Dated July 6, 2016](/wp-content/uploads/2016/07/BPTH_8-K_20160706.pdf)\n\n[July 1, 2016SEC Form 8-K: Entry Into a Material Definitive Agreement, Other Events](/wp-content/uploads/2016/07/BPTH_8-K_Agreement_20160701.pdf)\n\n[July 1, 2016PROSPECTUS SUPPLEMENT (To Prospectus dated January 13, 2014)](/wp-content/uploads/2016/07/BPTH_Pros_Supp_20160701.pdf)\n\n[July 1, 2016SEC Form 8-K: Press Release Dated June 28, 2016](/wp-content/uploads/2016/07/BPTH_Form_8K_TJU_20160701.pdf)\n\n[June 6, 2016SEC FORM 8-K – Press Release Dated June 6, 2016](/wp-content/uploads/2016/06/BPTH_8K_20160606.pdf)\n\n[May 20, 2016SEC FORM 8-K – Press Release Dated May 19, 2016](/wp-content/uploads/2016/05/BPTH_8K_20160520.pdf)\n\n[May 11, 2016SEC FORM 10-Q – For Period Ending March 31, 2016](/wp-content/uploads/2016/05/10_Q-_20160331.pdf)\n\n[May 11, 2016Interactive Data Files for 10-Q (Zipped)](/wp-content/uploads/2016/05/bpth-20160331.zip)\n\n[May 11, 2016SEC FORM 8-K – Press Release Dated May 11, 2016](/wp-content/uploads/2016/05/BPTH_8-K_20160511.pdf)\n\n[May 5, 2016SEC FORM 8-K – Press Release Dated May 5, 2016](/wp-content/uploads/2016/05/BPTH_8K_20160505.pdf)\n\n[March 24, 2016SEC FORM 8-K – Press Release Dated March 23, 2016](/wp-content/uploads/2016/05/BPTH_8K_20160324.pdf)\n\n[March 16, 2016SEC FORM 8-K – Press Release Dated March 15, 2016](/wp-content/uploads/2016/05/bpth_8K_20160316.pdf)\n\n[March 15, 2016SEC FORM 10-K – Fiscal Year Ended December 31, 2015](/wp-content/uploads/2016/05/BPTH_10-K_20160315.pdf)\n\n[March 15, 2016Interactive Data Files (XBRL) For FORM 10-K – For Fiscal Year Ending December 31, 2015](/wp-content/uploads/2016/05/bpth-20151231.zip)\n\n[March 8, 2016SEC FORM 8-K – Press Release Dated March 8, 2016](/wp-content/uploads/2016/05/BPTH_8-K_20160308-1.pdf)\n\n[March 7, 2016SEC FORM 8-K – Press Release Dated March 7, 2016](/wp-content/uploads/2016/05/BPTH_8-K_20160307.pdf)\n\n[March 4, 2016SEC FORM 8-K – Press Release Dated March 3, 2016](/wp-content/uploads/2016/05/BPTH_8_K_20160304.pdf)\n\n[February 1, 2016SEC FORM 8-K – Press Release Dated February 1, 2016](/wp-content/uploads/2016/05/BPTH_8K_20160201.pdf)\n\n[January 13, 2016SEC FORM 8-K – Slide Presentation Dated January 2016](/wp-content/uploads/2016/05/BPTH_8-K_20160113.pdf)\n\n[January 6, 2016SEC FORM 8-K – Press Release Dated January 6, 2016](/wp-content/uploads/2016/05/bpth_8_K_20160106.pdf)\n\n[December 29, 2015SEC FORM 8-K – Submission of Matters to a Vote of Security Holders](/wp-content/uploads/2016/05/BPTH_8_K_20151230.pdf)\n\n[December 8, 2015SEC FORM 8-K – Press Release Dated December 8, 2015](/wp-content/uploads/2016/05/Bpth_8_K_2015_12_08.pdf)\n\n[November 12, 2015SEC SCHEDULE 14A – Definitive Proxy Statement](/wp-content/uploads/2016/05/bpth_DEF14A_20151112.pdf)\n\n[November 12, 2015SEC SCHEDULE 14A ADDITIONAL PROXY MATERIAL](/wp-content/uploads/2016/05/bpth_DEF14A_Additional_20151112.pdf)\n\n[November 12, 20152014 Annual Report – SEC Form 10-K](/wp-content/uploads/2016/05/bpth_10K_20151112.pdf)\n\n[November 10, 2015SEC FORM 8-K – Press Release Dated November 10, 2015](/wp-content/uploads/2016/05/BPTH_8-K_20151110.pdf)\n\n[November 9, 2015SEC FORM 10-Q – For Period Ending September 30, 2015](/wp-content/uploads/2016/05/Bpth_10-Q_20151109.pdf)\n\n[November 9, 2015Interactive Data Files (XBRL) For FORM 10-Q – For Period Ending September 30, 2015](/wp-content/uploads/2016/05/bpth-20150930.zip)\n\n[November 5, 2015SEC FORM 8-K – Press Release Dated Novembeer 5, 2015](/wp-content/uploads/2016/05/BPTH_8-K20151105.pdf)\n\n[October 14, 2015SEC FORM 8-K – Press Release Dated October 13, 2015](/wp-content/uploads/2016/05/BPTH_8_K_20151014.pdf)\n\n[October 9, 2015SEC FORM 8-K – Press Release Dated October 9, 2015](/wp-content/uploads/2016/05/BPTH_8-K20151009.pdf)\n\n[September 2, 2015SEC FORM 8-K – Press Release Dated September 2, 2015](/wp-content/uploads/2016/05/BPTH_8K09022015.pdf)\n\n[September 1, 2015SEC FORM 8-K – Press Release Dated August 31, 2015](/wp-content/uploads/2016/05/BPTH_8_K_20150901.pdf)\n\n[August 12, 2015SEC FORM 8-K – Press Release Dated August 11, 2015](/wp-content/uploads/2016/05/Bpth_8-K_20150812.pdf)\n\n[August 10, 2015SEC FORM 10-Q – Period Ending June 30, 2015](/wp-content/uploads/2016/05/Bpth10_Q_20150810.pdf)\n\n[August 10, 2015Interactive Data Files (XBRL) For FORM 10-Q – For Period Ending June 30, 2015](/wp-content/uploads/2016/05/bpth-20150630.zip)\n\n[July 15, 2015SEC FORM 4 – Statement of Changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_20150709.pdf)\n\n[July 13, 2015SEC FORM 4 – Statement of Changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_20150713.pdf)\n\n[July 9, 2015SEC FORM 4 – Statement of Changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_20150709-1.pdf)\n\n[June 25, 2015SEC FORM 8-K – Entry into a Material Definitive Agreement, Financial Statements and Exhibits](/wp-content/uploads/2016/05/BPTH_8-K_20150625.pdf)\n\n[June 25, 2015PROSPECTUS SUPPLEMENT – To Prospectus Dated January 13, 2014](/wp-content/uploads/2016/05/BPTH_ProspectusSupp20150625.pdf)\n\n[June 4, 2015SEC FORM 8-K – Other Events](/wp-content/uploads/2016/05/BPTH_8K_20150604.pdf)\n\n[May 12, 2015SEC FORM 8-K – Press Release Dated May 12, 2015](/wp-content/uploads/2016/05/Bpth1Q2015Results-1.pdf)\n\n[May 11, 2015SEC FORM 10-Q – Period Ending March 31, 2015](/wp-content/uploads/2016/05/BPTH_10Q_20150331.pdf)\n\n[May 11, 2015Interactive Data Files (XBRL) For FORM 10-Q – For Period Ending March 31, 2015](/wp-content/uploads/2016/05/bpth-20150331.zip)\n\n[May 4, 2015SEC FORM 4 – Statement of changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_20150504.pdf)\n\n[April 28, 2015SEC FORM 8-K – Press Release Dated April 28, 2015](/wp-content/uploads/2016/05/BPTH_8_K20150428.pdf)\n\n[April 24, 2015SEC FORM 8-K – Press Release Dated April 24, 2015](/wp-content/uploads/2016/05/BPTH_8_K20150424.pdf)\n\n[April 22, 2015SEC FORM 8-K – Press Release Dated April 22, 2015](/wp-content/uploads/2016/05/BPTH_8_K_20150422.pdf)\n\n[April 16, 2015SEC FORM 8-K – New Form of Indemnification Agreement](/wp-content/uploads/2016/05/8_K_20150416.pdf)\n\n[March 17, 2015SEC FORM 8-K – Press Release Dated March 17, 2015](/wp-content/uploads/2016/05/Bpth_8-K_20150317.pdf)\n\n[March 16, 2015SEC FORM 10-K – Fiscal Year Ended December 31, 2014](/wp-content/uploads/2016/05/Bpth_10K_20150316.pdf)\n\n[March 16, 2015Interactive Data Files (XBRL) For FORM 10-K – For Fiscal Year Ending December 31, 2014](/wp-content/uploads/2016/05/bpth-20141231.zip)\n\n[March 6, 2015SEC FORM 4 – Statement of changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_20150306.pdf)\n\n[March 5, 2015SEC FORM 8-K – Press Release Dated March 5, 2015](/wp-content/uploads/2016/05/8-K_2015_03_05.pdf)\n\n[March 4, 2015SEC FORM 4 – Statement of changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_20150304_4.pdf)\n\n[March 4, 2015SEC FORM 4 – Statement of changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_20150304_3.pdf)\n\n[March 4, 2015SEC FORM 4 – Statement of changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_20150304_2.pdf)\n\n[March 4, 2015SEC FORM 4 – Statement of changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_20150304_1.pdf)\n\n[February 10, 2015SEC FORM 8-K – Press Release Dated February 9, 2015](/wp-content/uploads/2016/05/bpth_8-K_2015_02_11.pdf)\n\n[January 8, 2015SEC FORM 8-K – Press Release Dated January 6, 2015](/wp-content/uploads/2016/05/Phase_II_starts-1.pdf)\n\n[January 6, 2015SEC FORM 8-K – Material Modification to Rights of Security Holders, Amendments, to Articles of Incorporation or Bylaws: Change in Fiscal Year, Submission of Matters to a Vote of Security Holders](/wp-content/uploads/2016/05/Bio-Path_Holdings_Inc_8-K_20150106.pdf)\n\n[December 23, 2014SEC FORM 8-K – Press Release Dated December 22, 2014](/wp-content/uploads/2016/05/Form_8_K_BPTH20141223.pdf)\n\n[November 14, 2014FORM 10-Q – Period Ending September 30, 2014](/wp-content/uploads/2014/11/BPTH_10Q_20141114.pdf)\n\n[November 14, 2014Interactive Data Files (XBRL) For FORM 10-Q – For Period Ending September 30, 2014](/wp-content/uploads/2016/05/bpth-20140930.zip)\n\n[November 13, 2014SEC SCHEDULE 14A – Definitive Proxy Statement](/wp-content/uploads/2016/05/BioPath_DEF_14A2014.pdf)\n\n[November 12, 2014SEC FORM 3 – Initial Statement of Beneficial Ownership of Securities](/wp-content/uploads/2016/05/SEC_FORM_3_20141112.pdf)\n\n[October 9, 2014SEC FORM 8-K – Press Release Dated October 7, 2014](/wp-content/uploads/2016/05/BPTH_8-K20141009.pdf)\n\n[October 3, 2014SEC FORM 4 – Statement of changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_20141003.pdf)\n\n[October 1, 2014SEC FORM 8-K – Press Release Dated September 30, 2014](/wp-content/uploads/2016/05/BPTH_8-K_20141001.pdf)\n\n[August 20, 2014SEC FORM 10-Q – Period Ending June 30, 2014](/wp-content/uploads/2016/05/BPTH_10-Q20140821.pdf)\n\n[August 20, 2014Interactive Data Files (XBRL) For FORM 10-Q – For Period Ending June 30, 2014](/wp-content/uploads/2016/05/bpth-20140630.zip)\n\n[August 18, 2014SEC FORM 8-K – Press Release Dated August 18, 2014](/wp-content/uploads/2016/05/BPTH_8-K20140818.pdf)\n\n[July 3, 2014SEC FORM 8-K – Termination of a Material Definitive Agreement, Change in Directors or Certain Officers, Press Release Dated June 30, 2014: Bio-Path Holdings Added to Russell Global, Russell 3000 and Russell Microcap Indexes](/wp-content/uploads/2016/05/Form_8_K_20140702.pdf)\n\n[June 20, 2014SEC FORM 8-K – Press Release Dated June 19, 2014: Enrollment Continues Into Bio-Path Holdings Phase I Clinical Trial](/wp-content/uploads/2016/05/BPTH_8_K_20140620-1.pdf)\n\n[May 20, 2014SEC FORM 8-K – Press Release Dated May 16, 2014: First Quarter 2014 Operational and Financial Results](/wp-content/uploads/2016/05/8-K_Bio-Path20140520.pdf)\n\n[May 15, 2014SEC FORM 10-Q – Period Ending March 31, 2014](/wp-content/uploads/2016/05/BPTH_10-Q_20140515.pdf)\n\n[May 15, 2014Interactive Data Files (XBRL) For FORM 10-Q – For Period Ending March 31, 2014](/wp-content/uploads/2016/05/bpth-20140331.zip)\n\n[May 5, 2014SEC FORM 4 – Statement of changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_20140505.pdf)\n\n[April 28, 2014SEC FORM 4 – Statement of changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_20140428.pdf)\n\n[April 18, 2014SEC FORM 8-K – Entry Into a Material Definitive Agreement](/wp-content/uploads/2016/05/Form_8_K_20140418.pdf)\n\n[April 2, 2014SEC FORM 8-K – Press Release Dated April 1, 2014](/wp-content/uploads/2016/05/Form_8-K_20140402.pdf)\n\n[March 31, 2014SEC FORM 10-K – For the Fiscal Year Ended December 31, 2013](/wp-content/uploads/2016/05/Form_10_K_20140331.pdf)\n\n[March 31, 2014Interactive Data Files (XBRL) For FORM 10-K – For Fiscal Year Ending December 31, 2013](/wp-content/uploads/2016/05/bpth-20131231.zip)\n\n[March 31, 2014SEC FORM 3 – Initial Statement of Beneficial Ownership of Securities](/wp-content/uploads/2016/05/SEC_FORM_3_20140331.pdf)\n\n[March 26, 2014SEC FORM 8-K – Appointment of Certain Officers, Press Release Dated March 26, 2014](/wp-content/uploads/2016/05/Form_8K_BPTH20140326.pdf)\n\n[March 14, 2014SEC FORM 3/A – [Amend] Initial Statement of Beneficial Ownership of Securities](/wp-content/uploads/2016/05/SEC_FORM_3_A_20140314.pdf)\n\n[March 5, 2014SEC FORM 8-A – Bio-Path Holdings Announces Uplisting to the NASDAQ Capital Market](/wp-content/uploads/2016/05/Form_8-A12B_20140305.pdf)\n\n[March 5, 2014SEC FORM 8-K – Press Release Dated March 5, 2014](/wp-content/uploads/2016/05/Form_8-K_20140305.pdf)\n\n[February 13, 2014SEC FORM 3 – Initial Statement of Beneficial Ownership of Securities](/wp-content/uploads/2016/05/SEC_FORM_3_20140213-1.pdf)\n\n[February 13, 2014SEC FORM 4 – Statement of Changes in Beneficial Ownership of Securities](/wp-content/uploads/2016/05/SEC_FORM_4_20140213-1.pdf)\n\n[February 13, 2014SEC FORM 8-K – Change in Directors or Principal Officers, Amendments to Articles of Incorporation or Bylaws, Change in Fiscal Year](/wp-content/uploads/2016/05/BPTH_8-K_20140213.pdf)\n\n[February 3, 2014SEC FORM 4 – Statement of Changes in Beneficial Ownership of Securities](/wp-content/uploads/2016/05/SEC_FORM_4_20140203.pdf)\n\n[January 21, 2014SEC FORM 8-K – Entry into Material Definitive Agreement, Financial Statements and Exhibits](/wp-content/uploads/2016/05/Form_8-K_20140121.pdf)\n\n[January 21, 2014Prospectus Supplement January 15](/wp-content/uploads/2016/05/Prospectus_Supplement_20140115.pdf)\n\n[January 21, 2014Prospectus Supplement January 20](/wp-content/uploads/2016/05/Prospectus_Supplement_20140120.pdf)\n\n[January 9, 2014SEC Form S-3/A – Amendment No. 2 to Form S-3](/wp-content/uploads/2016/05/Form_S-3A_2014_01_09.pdf)\n\n[January 7, 2014SEC FORM 8-K – Press Release – Presentation at Biotech Showcase 2014](/wp-content/uploads/2016/05/Form_8-K_Presentation_at_Biotech_Showcase_2014.pdf)\n\n[December 19, 2013SEC FORM 8-K – Submission of Matters to a Vote of Security Holders](/wp-content/uploads/2016/05/Form_8-K_20131219.pdf)\n\n[December 10, 2013SEC FORM 8-K – Other Events, Press Release Dated December 9, 2013](/wp-content/uploads/2016/05/Form_8-K_Press_Release_ASH_Presentation.pdf)\n\n[December 5, 2013SEC FORM S-3/A – Amendment No. 1 to Form S-3](/wp-content/uploads/2016/05/S3ANo120131205.pdf)\n\n[November 18, 2013SEC FORM 8-K – Press Release Dated November 15, 2013](/wp-content/uploads/2016/05/Form_8-K_20131118.pdf)\n\n[November 18, 2013SEC FORM 10-Q/A – Amendment No 1](/wp-content/uploads/2016/05/Form_10-QA_20131118.pdf)\n\n[November 18, 2013XBRL FILES FOR FORM 10-Q/A – For September 30, 2013](/wp-content/uploads/2016/05/BPTH_20130930_XBRL_files.zip)\n\n[November 14, 2013SEC FORM 10-Q – Quarterly Report For Period Ending September 30, 2013](/wp-content/uploads/2016/05/Form_10Q_20130930.pdf)\n\n[November 8, 2013SEC FORM 8-K – Press Release Dated November 7, 2013](/wp-content/uploads/2016/05/BPTH_Form_8-K_Presentation_at_ASH_Annual_Meeting.pdf)\n\n[November 5, 2013SEC FORM S-3 – Registration Statement](/wp-content/uploads/2016/05/Form_S-3_20131115.pdf)\n\n[October 31, 2013SEC FORM SCHEDULE 14A – Definitive Proxy Statement](/wp-content/uploads/2016/05/Bio-Path_Sched14AProxy.pdf)\n\n[October 3, 2013SEC FORM 8-K – Unregistered Sale of Equity Securities, Press Release Dated October 1, 2013](/wp-content/uploads/2016/05/Bio-Path_Form_8-K__Closing_of_Offering_and_10_01_13_PR.pdf)\n\n[October 2, 2013SEC FORM 4 – Statement of changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_20131002.pdf)\n\n[September 20, 2013SEC FORM 8-K – Press Release Dated September 19, 2013](/wp-content/uploads/2016/05/Form_8-K_re__Appointment_of_Maxim.pdf)\n\n[August 15, 2013SEC FORM 8-K – Press Release Dated August 15, 2013](/wp-content/uploads/2016/05/Form_8-K_2013_Second_Quarter_Earnings_Release.pdf)\n\n[August 15, 2013SEC FORM 10-Q – Quarterly Report For Period Ending June 30, 2013](/wp-content/uploads/2016/05/Bio-Path-Holdings_Inc._10-Q_08142013.pdf)\n\n[August 15, 2013XBRL FILES FOR FORM 10-Q – For June 30, 2013](/wp-content/uploads/2016/05/BPTH_xbrl-files_20130815.zip)\n\n[August 12, 2013SEC FORM 4 – Statement of changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_20130812.pdf)\n\n[August 12, 2013SEC FORM 4 – Statement of changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_2_20130812.pdf)\n\n[August 9, 2013SEC FORM 8-K – Press Release Dated August 9, 2013](/wp-content/uploads/2016/05/Form_8-K_08_09_2013.pdf)\n\n[July 22, 2013SEC FORM 8-K – Press Release Dated July 22, 2013](/wp-content/uploads/2016/05/Bio_Path_Form_8-K_PR_2013_07_22.pdf)\n\n[July 7, 2013SEC FORM 8-K – Press Release Dated June 6, 2013](/wp-content/uploads/2016/05/Form_8-K_Press_Release_Completes_Fifth_Corhort.pdf)\n\n[May 16, 2013SEC FORM 8-K – Press Release Dated May 16, 2013](/wp-content/uploads/2016/05/Form_8K_bpth_20130516_1qtr_earnings.pdf)\n\n[May 15, 2013SEC FORM 10-Q – Period Ending March 31, 2013](/wp-content/uploads/2016/05/Form_10Q_20130515.pdf)\n\n[May 15, 2013XBRL FILES FOR FORM 10-Q – For March 31, 2013](/wp-content/uploads/2016/05/BPTH_20130331.zip)\n\n[April 26, 2013SEC FORM 4 – Statement of changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_20130426.pdf)\n\n[April 4, 2013SEC FORM 8-K – Press Release Dated April 2, 2013](/wp-content/uploads/2016/05/Form_8-K_2012_Annual_Earnings_Release.pdf)\n\n[April 1, 2013SEC FORM 10-K – Fiscal Year Ended December 31, 2012](/wp-content/uploads/2016/05/Form_10K2012_2013_04_01_Bio-Path.pdf)\n\n[April 1, 201310-K Interactive Data Files (XBRL)](/wp-content/uploads/2016/05/BIO-PATH-HOLDINGS-INC_0001133818_DFN-10K20121231.zip)\n\n[March 12, 2013SEC FORM 8-K – Press Release Dated March 12, 2013](/wp-content/uploads/2016/05/Form_8-K_2013_03_PR_Fifth_Cohort.pdf)\n\n[February 21, 2013SEC FORM 4 – Statement of changes in beneficial ownership of securities](/wp-content/uploads/2016/05/SEC_FORM_4_20130221.pdf)\n\n[January 23, 2013SEC FORM 10-K/A – Amendment No. 1 For Fiscal Year Ended December 31, 2011](/wp-content/uploads/2016/05/BPTH_10KA_20130123.pdf)\n\n[January 4, 2013SEC FORM 8-K – Press Release Dated January 3, 2013](/wp-content/uploads/2016/05/Form_8-K_Presentation_at_Biotech_Showcase_2013_Conference.pdf)\n\n[December 17, 2012SEC FORM 8-K – Submission of Matters to a Vote of Security Holders](/wp-content/uploads/2016/05/Bio-Path_Form_8-k_re_2012Annual_Meeting.pdf)\n\n[December 7, 2012SEC FORM 8-K – Press Release Dated December 6, 2012](/wp-content/uploads/2016/05/8K_TNBC_and_IBC_Treatment_Development_Dec_2012.pdf)\n\n[November 16, 2012SEC FORM 8-K – Press Release Dated Nov 14 & Nov 16, 2012](/wp-content/uploads/2016/05/Form_8-K_Press_release_re_4th_Cohort_and_Earnings_Release.pdf)\n\n[November 15, 2012SEC FORM 10-Q – Period Ending September 30, 2012](/wp-content/uploads/2016/05/BIOPATH_10Q_20121114.pdf)\n\n[November 15, 201210-Q Interactive Data Files (XBRL)](/wp-content/uploads/2016/05/BPTH_XBRL_10Q20120930.zip)\n\n[October 29, 2012SEC SCHEDULE 14A – Definitive Proxy Statement](/wp-content/uploads/2016/05/SCHED14AProxy.pdf)\n\n[October 3, 2012SEC FORM 8-K – Press Release Dated October 3, 2012 -Bio-Path Holdings to Present at 11th Annual BIO Investor Forum](/wp-content/uploads/2016/05/Form8-K_2012_10_03.pdf)\n\n[October 3, 2012SEC FORM 8-K – Press Release Dated October 3, 2012 – Press Release: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers](/wp-content/uploads/2016/05/Form_8-K_appointment_of_M_Garrison_to_board.pdf)\n\n[September 5, 2012SEC FORM 8-K – Press Release Dated September 5, 2012](/wp-content/uploads/2016/05/Form_8-K_2012_09_04_Rodman__Renshaw.pdf)\n\n[August 24, 2012SEC FORM 8-K – Press Release Dated Aug 24, 2012: Bio-Path Holdings to Present at the 2012 Southern California Investor Conference](/wp-content/uploads/2016/05/Form8-K_20120824.pdf)\n\n[August 16, 2012SEC FORM 8-K – Press Release: Bio-Path Reports Second Quarter 2012 Operational and Financial Results](/wp-content/uploads/2016/05/Form8-K2012_2nd_Qtr_Earnings_Release.pdf)\n\n[August 14, 2012SEC FORM 10-Q – Period Ending June 30, 2012](/wp-content/uploads/2016/05/Form10Q20120630BPTH.pdf)\n\n[August 14, 201210-Q Interactive Data Files (XBRL)](/wp-content/uploads/2016/05/bpth-20120630.zip)\n\n[July 25, 2012SEC FORM 8-K – Press Release Dated July 25, 2012](/wp-content/uploads/2016/05/8KStartCohort4Jul2012_001.pdf)\n\n[June 4, 2012SEC FORM 8-K – Press Release Dated June 4, 2012](/wp-content/uploads/2016/05/Form_8-K_2012_06_04.pdf)\n\n[May 29, 2012SEC FORM 8-K – Press Release Dated May 29, 2012](/wp-content/uploads/2016/05/8K-Third-Cohort-Complete.pdf)\n\n[May 22, 2012SEC FORM D – Notice of Exempt Offering of Securities](/wp-content/uploads/2016/05/Form_D_20120522.pdf)\n\n[May 17, 2012SEC FORM 8-K – Press Release Results of Operations and Financial Condition Dated May 17, 2012](/wp-content/uploads/2016/05/Form_8-K_1Q2012_earnings_release.pdf)\n\n[May 15, 2012SEC FORM 10-Q – Period Ending March 31, 2012](/wp-content/uploads/2016/05/Form_10-Q_2012_03_31.pdf)\n\n[May 15, 201210-Q Interactive Data Files (XBRL)](/wp-content/uploads/2016/05/BPTH-10-Q-XBRL-Data-Files.zip)\n\n[May 15, 2012PROSPECTUS SUPPLEMENT – To Prospectus Dated July 29, 2010](/wp-content/uploads/2016/05/Prospectus_Supplement10-Q_2012_03_31.pdf)\n\n[April 3, 2012SEC FORM 8-K – 2011 Fiscal Year End Results and Press Release](/wp-content/uploads/2016/05/Form_8-K_BPTH_2011_fiscal_year_PR-.pdf)\n\n[March 30, 2012SEC FORM 10-K – Period Ending December 31, 2011](/wp-content/uploads/2016/05/Form10K_20120330_Bpth.pdf)\n\n[March 30, 201210-K Interactive Data Files (XBRL)](/wp-content/uploads/2016/05/bpth-20111231.zip)\n\n[February 7, 2012SEC FORM 8-K – Press Release Bio-Path Holdings Successfully Completes Second Cohort in Phase I Clinical Trial](/wp-content/uploads/2016/05/Form8k20120207.pdf)\n\n[January 4, 2012SEC FORM 8-K Press Release Bio-Path Holdings to Present at the Biotech Showcase 2012 Conference](/wp-content/uploads/2016/05/Form-8K_2012_01_04.pdf)\n\n[November 15, 2011SEC FORM 10-Q – Period Ending September 30, 2011](/wp-content/uploads/2016/05/Form_10Q_3Q_2011.pdf)\n\n[November 15, 201110-Q Interactive Data Files (XBRL)](/wp-content/uploads/2016/05/bpth-20110930.zip)\n\n[November 15, 2011SEC FORM 8-K – Press Release : 2011 3rd Quarter Financial Results](/wp-content/uploads/2016/05/Form_8-K_3Q_earnings.pdf)\n\n[October 20, 2011SEC FORM 8-K – Press Release : Bio-Path Holdings to Present at the 10th Annual BIO Investor Forum](/wp-content/uploads/2016/05/Form_8_K_BioPath_Presents_at_Bio_Forum.pdf)\n\n[October 4, 2011SEC Form 8-K Press Release : Initial Data From Bio-Path Holdings’ Phase I Clinical Trial Accepted for Presentation at American Society of Hematology Annual Meeting](/wp-content/uploads/2016/05/Form_8K_Bpth_2011_10_04.pdf)\n\n[August 15, 2011SEC Form 8-K Press Release : Financial Statements and Exhibits](/wp-content/uploads/2016/05/Form_8K_20110815.pdf)\n\n[August 15, 2011SEC Form 10-Q Period Ending June 30, 2011](/wp-content/uploads/2016/05/Form_10Q-20110630.pdf)\n\n[August 15, 201110-Q Interactive Data Files (XBRL)](/wp-content/uploads/2016/05/bpth-20110630.zip)\n\n[May 17, 2011SEC Form 10-Q Period Ending March 31, 2011](/wp-content/uploads/2016/05/Form10Q20110331.pdf)\n\n[May 17, 2011SEC Form 8-K – Press Release : Results of Financial Condition](/wp-content/uploads/2016/05/Form8K20110517.pdf)\n\n[March 31, 2011SEC FORM 10-K – Period Ending December 31, 2010](/wp-content/uploads/2016/05/BPTH_Form-10K_20110331.pdf)\n\n[November 15, 2010SEC FORM 10-Q Period Ending September 30, 2010](/wp-content/uploads/2016/05/10QBioPath20100930.pdf)\n\n[November 9, 2010SEC FORM 8-K Shareholder Meeting November 2010](/wp-content/uploads/2016/05/8-K-Shareholder-Meeting-Nov-2010.pdf)\n\n[September 20, 2010SEC FORM 8-K – Departure of Directors or Certain Officers](/wp-content/uploads/2016/05/frm8k20100920.pdf)\n\n[August 17, 2010SEC FORM 8-K – Exhibits – Press Release](/wp-content/uploads/2016/05/form8K_8_17_2010.pdf)\n\n[August 16, 2010SEC FORM 10-Q – Period Ending June 30, 2010](/wp-content/uploads/2016/05/form10Q_8_16_2010.pdf)\n\n[July 8, 2010SEC Amendment No. 2 to Form S-1 – Registration Statement Under the Securities Act Of 1933](/wp-content/uploads/2016/05/Amend_No2_to_Form_S-1.pdf)\n\n[July 1, 2010SEC Amendment No. 1 to Form S-1 – Registration Statement Under the Securities Act Of 1933](/wp-content/uploads/2016/05/Amend_No1_to_Form_S-1.pdf)\n\n[June 21, 2010SEC Form 8-K – Amendments to Articles of Incorporation or Bylaws: Change in fiscal Year](/wp-content/uploads/2016/05/Form_8-K20100621.pdf)\n\n[June 17, 2010SEC FORM S-1 – Registration Statement Under the Securities Act of 1933](/wp-content/uploads/2016/05/FormS120100617.pdf)\n\n[June 4, 2010SEC FORM 8-K – Entry into a Material Definitive Agreement, Unregistered Sale of Equity Sec](/wp-content/uploads/2016/05/frm8k060410bpth.pdf)\n\n[May 17, 2010SEC FORM 10-Q – Period Ending March 31, 2010](/wp-content/uploads/2016/05/form10Q03312010.pdf)\n\n[March 31, 2010SEC FORM 10-K – Period Ending December 31, 2009](/wp-content/uploads/2016/05/10K033110.pdf)\n\n[March 15, 2010SEC FORM 8-K – Other Events – Press release](/wp-content/uploads/2016/05/fm8k-031510.pdf)\n\n[November 15, 2009SEC FORM 10-Q – Period Ending September 30, 2009](/wp-content/uploads/2016/05/form10Q09302009-1.pdf)\n\n[November 2, 2009SEC FORM 8-K – Other Events, Exhibits](/wp-content/uploads/2016/05/frm8k11022009.pdf)\n\n[August 15, 2009SEC FORM 10-Q – Period Ending June 30, 2009](/wp-content/uploads/2016/05/10Q090630.pdf)\n\n[May 18, 2009SEC FORM 10-Q – Period Ending March 31, 2009](/wp-content/uploads/2016/05/BPTHForm10Q200903.pdf)\n\n[April 3, 2009SEC FORM 10-K – Period Ending December 31, 2008](/wp-content/uploads/2016/05/10K123108.pdf)\n\n[April 3, 2009Exhibits for 10-K – Period Ending December 31, 2008](/wp-content/uploads/2016/05/Exhibits10K.pdf)\n\n[December 10, 2008SEC FORM 8-S – Bio-Path Holdings, Inc. – First Amended 2007 Stock Incentive Plan](/wp-content/uploads/2016/05/Form_S8_121008.pdf)\n\n[November 14, 2008SEC Form 10-Q – Quarterly Report Period ended September 30, 2008](/wp-content/uploads/2016/05/10QSB080814.pdf)\n\n[October 16, 2008SEC FORM 8-K – Material Agreement, Financial Statements](/wp-content/uploads/2016/05/8-KAltheaAgreement_ExhibitFinal.pdf)\n\n[October 14, 2008SEC FORM 4](/wp-content/uploads/2016/05/SEC_Form4Filing.pdf)\n\n[September 10, 2008SEC Form 3](/wp-content/uploads/2016/05/SEC_Form3Filing.pdf)\n\n[August 19, 2008SEC FORM 8-K – Change In Directors, Principal Officers](/wp-content/uploads/2016/05/8-KUlrichMuellerResignation.pdf)\n\n[August 14, 2008SEC Form 10-Q – Quarterly Report Period ended June 30, 2008](/wp-content/uploads/2016/05/10QSB080814-1.pdf)\n\n[June 24, 2008SEC FORM 8-K](/wp-content/uploads/2016/05/fm8k0608.pdf)\n\n[May 20, 2008SEC Form 10-Q – Quarterly Report Period ended March 31, 2008](/wp-content/uploads/2016/05/10QSB080520.pdf)\n\n[May 19, 2008SEC FORM 8-K/A – Exhibits, Audited Financial Statements](/wp-content/uploads/2016/05/8KA051908.pdf)\n\n[March 3, 2008SEC Form 8-K – Changes In Registrant’s Certifying Accountant](/wp-content/uploads/2016/05/form8k03032008.pdf)\n\n[February 19, 2008SEC FORM 8-K – Completion of Acquisition or Disposition of Assets](/wp-content/uploads/2016/05/form8K02192008.pdf)\n\n[![logo](https://biopath.wpengine.com/wp-content/uploads/2021/09/BPTHlogo.png)](/)\n\n  * [About Bio-Path](https://www.biopathholdings.com/about/)\n    * [Overview](https://www.biopathholdings.com/about/)\n    * [Leadership](https://www.biopathholdings.com/about/leadership/)\n    * [Board of Directors](https://www.biopathholdings.com/about/board-of-directors/)\n    * [Scientific Advisory Board](https://www.biopathholdings.com/about/scientific-advisory-board/)\n    * [Partnering Opportunities](https://www.biopathholdings.com/about/partnering-opportunities/)\n  * [Technology](https://www.biopathholdings.com/technology/)\n  * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Prexigebersen](https://www.biopathholdings.com/pipeline/prexigebersen/)\n    * [BP1001-A](https://www.biopathholdings.com/pipeline/bp1001-a/)\n    * [BP1002](https://www.biopathholdings.com/pipeline/bp1002/)\n    * [BP1003](https://www.biopathholdings.com/pipeline/bp1003/)\n  * [Patients](https://www.biopathholdings.com/patients/)\n  * [Investors](https://www.biopathholdings.com/investors/)\n    * [Overview](https://www.biopathholdings.com/investors/)\n    * [SEC Filings](https://www.biopathholdings.com/investors/sec-filings/)\n    * [Corporate Governance](https://www.biopathholdings.com/investors/corporate-governance/)\n  * [Media](https://www.biopathholdings.com/media/)\n    * [Press Releases](https://www.biopathholdings.com/media/)\n    * [Events](https://www.biopathholdings.com/media/events/)\n    * [Presentations & Publications](https://www.biopathholdings.com/media/presentations-publications/)\n  * [Careers](https://www.biopathholdings.com/careers/)\n  * [Contact Us](https://www.biopathholdings.com/contact-us/)\n\n\n"
        }
      ]
    },
    {
      "section_name": "Corporate Governance",
      "links": [
        {
          "title": "Corporate Governance",
          "url": "https://www.biopathholdings.com/investors/corporate-governance/",
          "content": "[![Bio-Path Holdings](/wp-content/uploads/2021/09/BPTHlogo.png)](https://www.biopathholdings.com/)\n\n  * [About Bio-Path](https://www.biopathholdings.com/about/)\n    * [Overview](https://www.biopathholdings.com/about/)\n    * [Leadership](https://www.biopathholdings.com/about/leadership/)\n    * [Board of Directors](https://www.biopathholdings.com/about/board-of-directors/)\n    * [Scientific Advisory Board](https://www.biopathholdings.com/about/scientific-advisory-board/)\n    * [Partnering Opportunities](https://www.biopathholdings.com/about/partnering-opportunities/)\n  * [Technology](https://www.biopathholdings.com/technology/)\n  * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Prexigebersen](https://www.biopathholdings.com/pipeline/prexigebersen/)\n    * [BP1001-A](https://www.biopathholdings.com/pipeline/bp1001-a/)\n    * [BP1002](https://www.biopathholdings.com/pipeline/bp1002/)\n    * [BP1003](https://www.biopathholdings.com/pipeline/bp1003/)\n  * [Patients](https://www.biopathholdings.com/patients/)\n  * [Investors](https://www.biopathholdings.com/investors/)\n    * [Overview](https://www.biopathholdings.com/investors/)\n    * [SEC Filings](https://www.biopathholdings.com/investors/sec-filings/)\n    * [Corporate Governance](https://www.biopathholdings.com/investors/corporate-governance/)\n  * [Media](https://www.biopathholdings.com/media/)\n    * [Press Releases](https://www.biopathholdings.com/media/)\n    * [Events](https://www.biopathholdings.com/media/events/)\n    * [Presentations & Publications](https://www.biopathholdings.com/media/presentations-publications/)\n  * [Careers](https://www.biopathholdings.com/careers/)\n  * [Contact Us](https://www.biopathholdings.com/contact-us/)\n\n\n\n[BPTH – Certificate of Amendment to Certificate of Incorporation (1-16-19)](/wp-content/uploads/2019/05/BPTH-Certificate-of-Amendment-to-Certificate-of-Incorporation-1-16-19.pdf)\n\n[BPTH – Certificate of Amendment to Certificate of Incorporation (2-7-18)](/wp-content/uploads/2019/05/BPTH-Certificate-of-Amendment-to-Certificate-of-Incorporation-2-7-18.pdf)\n\n[Bylaws](/wp-content/uploads/2017/06/BPTH_First_Amended_and_Restated_Bylaws.pdf)\n\n[Amendment No. 1 to First Amended and Restated Bylaws](https://www.biopathholdings.com/wp-content/uploads/2023/12/2023_SecretaryCertification_ByLaws_oneThird.pdf)\n\n[Nominating/Corporate Governance Committee Charter](/wp-content/uploads/2016/04/Nominating_Corporate_Governance_Committee_Charter.pdf)\n\n[Compensation Committee Charter](/wp-content/uploads/2016/04/BPTH_Compensation_Committee_Charter1.pdf)\n\n[Audit Committee Charter](/wp-content/uploads/2016/04/BPTH_Audit_Committee_Charter__Final1.pdf)\n\n[Corporate Governance Guidelines](https://www.biopathholdings.com/wp-content/uploads/2016/04/Corporate_Governance_Guidelines.pdf)\n\n[Code of Business Conduct and Ethics for Members of the Board of Directors](/wp-content/uploads/2016/04/BPTH_Code_of_Business_Conduct_Ethics_for_Board.pdf)\n\n[Employee Code of Business Conduct and Ethics](/wp-content/uploads/2016/04/BPTH_Employee_Code_of_Business_Conduct_Ethics.pdf)\n\n[Certificate of Incorporation](/wp-content/uploads/2016/04/BPTH_Certificate_of_Incorporation_DE.pdf)\n\n[Pre-approval Access Policy](/wp-content/uploads/2018/04/preapproval-access-policy.pdf)\n\n[![logo](https://biopath.wpengine.com/wp-content/uploads/2021/09/BPTHlogo.png)](/)\n\n  * [About Bio-Path](https://www.biopathholdings.com/about/)\n    * [Overview](https://www.biopathholdings.com/about/)\n    * [Leadership](https://www.biopathholdings.com/about/leadership/)\n    * [Board of Directors](https://www.biopathholdings.com/about/board-of-directors/)\n    * [Scientific Advisory Board](https://www.biopathholdings.com/about/scientific-advisory-board/)\n    * [Partnering Opportunities](https://www.biopathholdings.com/about/partnering-opportunities/)\n  * [Technology](https://www.biopathholdings.com/technology/)\n  * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Prexigebersen](https://www.biopathholdings.com/pipeline/prexigebersen/)\n    * [BP1001-A](https://www.biopathholdings.com/pipeline/bp1001-a/)\n    * [BP1002](https://www.biopathholdings.com/pipeline/bp1002/)\n    * [BP1003](https://www.biopathholdings.com/pipeline/bp1003/)\n  * [Patients](https://www.biopathholdings.com/patients/)\n  * [Investors](https://www.biopathholdings.com/investors/)\n    * [Overview](https://www.biopathholdings.com/investors/)\n    * [SEC Filings](https://www.biopathholdings.com/investors/sec-filings/)\n    * [Corporate Governance](https://www.biopathholdings.com/investors/corporate-governance/)\n  * [Media](https://www.biopathholdings.com/media/)\n    * [Press Releases](https://www.biopathholdings.com/media/)\n    * [Events](https://www.biopathholdings.com/media/events/)\n    * [Presentations & Publications](https://www.biopathholdings.com/media/presentations-publications/)\n  * [Careers](https://www.biopathholdings.com/careers/)\n  * [Contact Us](https://www.biopathholdings.com/contact-us/)\n\n\n"
        }
      ]
    },
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://www.biopathholdings.com/media/",
          "content": "[![Bio-Path Holdings](/wp-content/uploads/2021/09/BPTHlogo.png)](https://www.biopathholdings.com/)\n\n  * [About Bio-Path](https://www.biopathholdings.com/about/)\n    * [Overview](https://www.biopathholdings.com/about/)\n    * [Leadership](https://www.biopathholdings.com/about/leadership/)\n    * [Board of Directors](https://www.biopathholdings.com/about/board-of-directors/)\n    * [Scientific Advisory Board](https://www.biopathholdings.com/about/scientific-advisory-board/)\n    * [Partnering Opportunities](https://www.biopathholdings.com/about/partnering-opportunities/)\n  * [Technology](https://www.biopathholdings.com/technology/)\n  * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Prexigebersen](https://www.biopathholdings.com/pipeline/prexigebersen/)\n    * [BP1001-A](https://www.biopathholdings.com/pipeline/bp1001-a/)\n    * [BP1002](https://www.biopathholdings.com/pipeline/bp1002/)\n    * [BP1003](https://www.biopathholdings.com/pipeline/bp1003/)\n  * [Patients](https://www.biopathholdings.com/patients/)\n  * [Investors](https://www.biopathholdings.com/investors/)\n    * [Overview](https://www.biopathholdings.com/investors/)\n    * [SEC Filings](https://www.biopathholdings.com/investors/sec-filings/)\n    * [Corporate Governance](https://www.biopathholdings.com/investors/corporate-governance/)\n  * [Media](https://www.biopathholdings.com/media/)\n    * [Press Releases](https://www.biopathholdings.com/media/)\n    * [Events](https://www.biopathholdings.com/media/events/)\n    * [Presentations & Publications](https://www.biopathholdings.com/media/presentations-publications/)\n  * [Careers](https://www.biopathholdings.com/careers/)\n  * [Contact Us](https://www.biopathholdings.com/contact-us/)\n\n\n\n[November 15, 2024Bio-Path Holdings Reports Third Quarter 2024 Financial Results](https://www.biopathholdings.com/wp-content/uploads/2024/11/BPTH_Third_Quarter_2024_Earnings_Release.pdf)\n\n[November 8, 2024Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/11/BPTH_Third_Quarter_2024_Earnings_Announcement.pdf)\n\n[October 10, 2024Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules](https://www.biopathholdings.com/wp-content/uploads/2024/10/BPTH-20241010_PIPE_Closing.pdf)\n\n[October 8, 2024Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity](https://www.biopathholdings.com/wp-content/uploads/2024/10/BP1001-A_Obesity_Program_Release.pdf)\n\n[September 16, 2024Bio-Path Holdings Announces Publication in Biomedicines](https://www.biopathholdings.com/wp-content/uploads/2024/09/BPTH_Biomedicines_Publication_Release.pdf)\n\n[September 3, 2024Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference](https://www.biopathholdings.com/wp-content/uploads/2024/09/BPTH_2024_HCW_Conference-Release.pdf)\n\n[August 21, 2024Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors](https://www.biopathholdings.com/wp-content/uploads/2024/08/BP1001-A_Solid_Tumor_Response_AML_Durability.pdf)\n\n[August 15, 2024Bio-Path Holdings Reports Second Quarter 2024 Financial Results](https://www.biopathholdings.com/wp-content/uploads/2024/08/BPTH_Second_Quarter_2024_Earnings_Release.pdf)\n\n[August 8, 2024Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/08/BPTH_Second_Quarter_2024_Earnings_Announcement.pdf)\n\nLoad More\n\n[July 8, 2024Bio-Path Holdings Provides Clinical Update and Expansion Plans](https://www.biopathholdings.com/wp-content/uploads/2024/07/BPTH_-Provides_Clinical_Update_and_Expansion_Plans.pdf)\n\n[June 14, 2024Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress](https://www.biopathholdings.com/wp-content/uploads/2024/06/BPTH_EHA_Data_Press_Release.pdf)\n\n[June 5, 2024Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules](https://www.biopathholdings.com/wp-content/uploads/2024/06/BPTH_PIPE_PR_20240605.pdf)\n\n[June 4, 2024Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules](https://www.biopathholdings.com/wp-content/uploads/2024/06/BPTH_PR_June_2024_PIPE.pdf)\n\n[June 3, 2024Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting](https://www.biopathholdings.com/wp-content/uploads/2024/06/BPTH-ASCO_Data_Press_Release.pdf)\n\n[May 24, 2024Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress](https://www.biopathholdings.com/wp-content/uploads/2024/05/BPTH_EHA_Announcement_Release.pdf)\n\n[May 23, 2024Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting](https://www.biopathholdings.com/wp-content/uploads/2024/05/BPTH_ASCO_Announcemen_2024.pdf)\n\n[May 15, 2024Bio-Path Holdings Reports First Quarter 2024 Financial Results](https://www.biopathholdings.com/wp-content/uploads/2024/05/BPTH_First_Quarter_2024-Earnings_Release.pdf)\n\n[May 9, 2024Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/05/BPTH_First_Quarter_2024_Earnings_Announcement.pdf)\n\n[April 18, 2024Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the- Market Under Nasdaq Rules](https://www.biopathholdings.com/wp-content/uploads/2024/04/BPTH_Press_Release_Intraday.pdf)\n\n[April 18, 2024Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients](https://www.biopathholdings.com/wp-content/uploads/2024/04/BPTH_Press_Release_20240418.pdf)\n\n[April 15, 2024Bio-Path Holdings Expands Global Patent Portfolio](https://www.biopathholdings.com/wp-content/uploads/2024/04/BPTH-IP-Update-Press-Release-2024-04-15.pdf)\n\n[April 2, 2024Bio-Path Holdings Provides 2024 Clinical and Operational Update](https://www.biopathholdings.com/wp-content/uploads/2024/04/Clinical_Program_Outlook_2024AL.pdf)\n\n[March 8, 2024BIO-PATH HOLDINGS REPORTS FULL YEAR 2023 FINANCIAL RESULTS](https://www.biopathholdings.com/wp-content/uploads/2024/03/BPTH_Year_End_2023_Earnings_Release.pdf)\n\n[March 1, 2024Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024](https://www.biopathholdings.com/wp-content/uploads/2024/03/BPTH-Fourth-Quarter-2023-Earnings-Announcement.pdf)\n\n[February 21, 2024Bio-Path Holdings Announces 1-for-20 Reverse Stock Split](https://www.biopathholdings.com/wp-content/uploads/2024/02/BPTH-Reverse_Stock_Spli000-Press_Release.pdf)\n\n[January 10, 2024Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients](https://www.biopathholdings.com/wp-content/uploads/2024/01/BP1002_First_Dose_Cohort_Complete_in_Lymphoma_Phase_1.pdf)\n\n[December 14, 2023Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia](https://www.biopathholdings.com/wp-content/uploads/2023/12/BPTH_BP1002_First_Dose_Cohort_Complete_R-R_AML-.pdf)\n\n[November 15, 2023BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS](https://www.biopathholdings.com/wp-content/uploads/2023/11/BPTH_Third_Quarter_2023_Earnings_Release.pdf)\n\n[November 8, 2023Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023](https://www.biopathholdings.com/wp-content/uploads/2023/11/BPTH_Third_Quarter2023_Earnings_Announcement.pdf)\n\n[October 24, 2023Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia](https://www.biopathholdings.com/wp-content/uploads/2023/10/BPTH_KOL_Event_Announcement.pdf)\n\n[September 8, 2023Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference](https://www.biopathholdings.com/wp-content/uploads/2023/09/BPTH_HC_Wainwright_Conference_Announcement_9-8-23.pdf)\n\n[August 15, 2023BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS](https://www.biopathholdings.com/wp-content/uploads/2023/08/BPTH_Second_Quarter_2023_Earnings_Release.pdf)\n\n[August 8, 2023Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023](https://www.biopathholdings.com/wp-content/uploads/2023/08/BPTH_Second_Quarter_2023_Earnings_Announcement.pdf)\n\n[August 3, 2023Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering](https://www.biopathholdings.com/wp-content/uploads/2023/08/BPTH-PressRelease-Summer_2023_Pricing.pdf)\n\n[August 1, 2023Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia](https://www.biopathholdings.com/wp-content/uploads/2023/08/Prexigeberson_Stage_2_Phase_2_AML_Interim_Results.pdf)\n\n[July 17, 2023Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors](https://www.biopathholdings.com/wp-content/uploads/2023/07/BP1001-A_Solid_Tumor_Completion_o_First_Dose_Cohort-v2.pdf)\n\n[May 12, 2023BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS](https://www.biopathholdings.com/wp-content/uploads/2023/05/BPTH_First_Quarter_2023_Earnings_Release.pdf)\n\n[May 5, 2023Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023](https://www.biopathholdings.com/wp-content/uploads/2023/05/BPTH_First_Quarter_2023_Earnings_Announcement.pdf)\n\n[March 31, 2023BIO-PATH HOLDINGS REPORTS FULL YEAR 2022 FINANCIAL RESULTS](https://www.biopathholdings.com/wp-content/uploads/2023/03/BPTH_Full_Year_and_Fourth_Quarter_2022_Earnings_Release.pdf)\n\n[March 24, 2023Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023](http://www.biopathholdings.com/wp-content/uploads/2023/03/BPTH_Fourth_Quarter_and_Full_Year_2022_Earnings_Announcement.pdf)\n\n[March 16, 2023Bio-Path Holdings Provides Clinical and Operational Update](https://www.biopathholdings.com/wp-content/uploads/2023/03/BPTH_2023_Clinical_Program_Outlook.pdf)\n\n[December 7, 2022Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors](https://www.biopathholdings.com/wp-content/uploads/2022/12/BPTH_BP1001-A_Solid_Tumor_FPD_Release.pdf)\n\n[November 15, 2022BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS](https://www.biopathholdings.com/wp-content/uploads/2022/11/BPTH-Third-Quarter-2022-Earnings-Release.pdf)\n\n[November 8, 2022Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022](https://www.biopathholdings.com/wp-content/uploads/2022/11/BPTH_Third_Quarter_2022_Earning_Announcement.pdf)\n\n[November 7, 2022Bio-Path Holdings Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement](https://www.biopathholdings.com/wp-content/uploads/2022/11/BPTH_Registered_Direct_Offering_20221107.pdf)\n\n[October 24, 2022Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in refractory/Relapsed Acute Myeloid Leukemia Patients](https://www.biopathholdings.com/wp-content/uploads/2022/10/BPTH_BP1002_First_Patient_Dosed_Release.pdf)\n\n[September 6, 2022Bio-Path Holdings to Present at H.C. Wainwright 24th Annual Global Investment Conference](https://www.biopathholdings.com/wp-content/uploads/2022/09/BPTH-HCW-Announcement-Release-2022-09-06.pdf)\n\n[August 16, 2022BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS](https://www.biopathholdings.com/wp-content/uploads/2022/08/BPTH_Second_Quarter_2022_Earnings_Release.pdf)\n\n[August 9, 2022Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022](https://www.biopathholdings.com/wp-content/uploads/2022/08/BPTH-Second-Quarter-2022-Earnings-Announcement-5-9-22-FINAL-Copy.pdf)\n\n[May 17, 2022BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS](https://www.biopathholdings.com/wp-content/uploads/2022/05/BPTH_First_Quarter_2022_Earnings.pdf)\n\n[May 10, 2022Bio-Path Holdings to Announce First Quarter 2022 Financial Results on May 17, 2022](https://www.biopathholdings.com/wp-content/uploads/2022/05/BPTH_First_Quarter_2022_Earnings_Announcementdocx.pdf)\n\n[April 12, 2022Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting￼](https://www.biopathholdings.com/wp-content/uploads/2022/04/BP1003_AACR_2022.pdf)\n\n[April 6, 2022Bio-Path Holdings Appoints Aline Sherwood to Board of Directors](https://www.biopathholdings.com/wp-content/uploads/2022/04/BPTH_Aline_Sherwood_Appointment.pdf)\n\n[March 11, 2022Bio-Path Holdings Reports Full Year 2021 Financial Results](https://www.biopathholdings.com/wp-content/uploads/2022/03/BPTH_Full_Year_2021_Earnings_Release.pdf)\n\n[March 8, 2022Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting](https://www.biopathholdings.com/wp-content/uploads/2022/03/BPTH_BP1003_AACR-2022.pdf)\n\n[March 4, 2022Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022](https://www.biopathholdings.com/wp-content/uploads/2022/03/BPTH-Year-End-2021-Earnings-Announcement.pdf)\n\n[January 5, 2022Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference](https://www.biopathholdings.com/wp-content/uploads/2022/01/BPTH_HCW_Announcement_20220105.pdf)\n\n[December 13, 2021Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting](/wp-content/uploads/2021/12/BP1001_ASH_2021_Data_Release_20211113.pdf)\n\n[November 12, 2021Bio-Path Holdings Reports Third Quarter 2021 Financial Results](/wp-content/uploads/2021/12/BPTH_3Q21_Earnings_Release_20211112.pdf)\n\n[November 5, 2021Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021](/wp-content/uploads/2021/12/BPTH_Third_Quarter_2021_Earnings_Announcement_20211105.pdf)\n\n[November 4, 2021Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting](/wp-content/uploads/2021/12/BP1001_ASH_20211104.pdf)\n\n[October 27, 2021Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors](/wp-content/uploads/2021/12/BPTH_BP101-A_Solid_Tumor_IND_20211027.pdf)\n\n[August 24, 2021Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients](/wp-content/uploads/2021/08/BPTH_BP1002_RR_AML_IND_Release.pdf)\n\n[August 13, 2021Bio-Path Holdings Reports Second Quarter 2021 Financial Results](/wp-content/uploads/2021/08/BPTH_2Q21_Earnings_Release.pdf)\n\n[August 6, 2021Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021](/wp-content/uploads/2021/08/BPTH_Second_Quarter_2021_Earnings_Announcement.pdf)\n\n[June 22, 2021Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003](/wp-content/uploads/2021/06/BPTH_STAT3_Patent_Release.pdf)\n\n[May 14, 2021Bio-Path Holdings Reports First Quarter 2021 Financial Results](/wp-content/uploads/2021/05/BPTH_1Q21_Earnings_Release.pdf)\n\n[May 7, 2021Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021](/wp-content/uploads/2021/05/BPTH_First_Quarter_2021_Earnings_Announcement.pdf)\n\n[April 22, 2021Bio-Path Announces Publication in Biomedicines](/wp-content/uploads/2021/04/BPTH_Biomedicines_Article_Release.pdf)\n\n[April 12, 2021Bio-Path Holdings Presents BP1002 Data at 2021 American Association for Cancer Research Annual Meeting](/wp-content/uploads/2021/04/BPTH_AACR_2021_Data_Release.pdf)\n\n[April 5, 2021Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia](/wp-content/uploads/2021/04/AML_Stage_2_Phase_2_Triple_Safety_Results.pdf)\n\n[March 11, 2021Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting](/wp-content/uploads/2021/03/BPTH_AACR_2021.pdf)\n\n[March 10, 2021BIO-PATH HOLDINGS REPORTS FULL YEAR 2020 FINANCIAL RESULTS](/wp-content/uploads/2021/03/BPTH_4Q20_Earnings_Release.pdf)\n\n[March 3, 2021Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021](/wp-content/uploads/2021/03/BPTH_Full_Year_2020_Earnings_Announcement.pdf)\n\n[February 18, 2021Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common Stock](/wp-content/uploads/2021/02/BPTH_PR_20210218.pdf)\n\n[February 16, 2021Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common Stock](/wp-content/uploads/2021/02/BPTH_Roth_Pricing_Press_Release.pdf)\n\n[February 13, 2021Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock](/wp-content/uploads/2021/02/BPTH_20210213_Press_Release.pdf)\n\n[February 10, 2021Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology](/wp-content/uploads/2021/02/BPTH_Patent_Grant_for_DNAbilize.pdf)\n\n[November 19, 2020Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002](/wp-content/uploads/2020/11/BPTH_BP1002_Initiation_Release.pdf)\n\n[November 13, 2020BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS](/wp-content/uploads/2020/11/BPTH_3Q20_EarningsRelease.pdf)\n\n[November 6, 2020Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020](/wp-content/uploads/2020/11/BPTH_3Q20-Earnings_Announcement.pdf)\n\n[October 22, 2020Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers](/wp-content/uploads/2020/10/BPTH-Patent-Allowance-Release.pdf)\n\n[September 9, 2020Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment Conference](/wp-content/uploads/2020/09/BPTH_HCW_Announcement_20200909.pdf)\n\n[August 14, 2020BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS](/wp-content/uploads/2020/08/BPTH_2Q20_Earnings_Release.pdf)\n\n[August 13, 2020Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia](/wp-content/uploads/2020/08/BPTH_AML_Phase_2_Amend.pdf)\n\n[August 10, 2020Bio-Path Holdings to Announce Second Quarter 2020 Financial Results on August 14, 2020](/wp-content/uploads/2020/08/BPTH_2Q20_Earnings_Announcement.pdf)\n\n[May 29, 2020Bio-Path Holdings Presents at 2020 American Society of Clinical Oncology Annual Meeting](/wp-content/uploads/2020/05/BPTH_ASCO_Poster_Presentation_2020.pdf)\n\n[May 15, 2020BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS](/wp-content/uploads/2020/05/BPTH_1Q20_Earnings_Release.pdf)\n\n[May 13, 2020Bio-Path Holdings to Present at the 2020 American Society of Clinical Oncology Annual Meeting](/wp-content/uploads/2020/05/BPTH_ASCO_2020_Release.pdf)\n\n[May 8, 2020Bio-Path Holdings to Announce First Quarter 2020 Financial Results on May 15, 2020](/wp-content/uploads/2020/05/BPTH_1Q20_Earnings_Announcement.pdf)\n\n[April 27, 2020Bio-Path Holdings Presents at 2020 American Association for Cancer Research Annual Meeting](/wp-content/uploads/2020/04/BPTH_Presents_at_2020_AACR_Annual_Meeting.pdf)\n\n[April 13, 2020Bio-Path Holdings to Present at the 2020 American Association for Cancer Research Annual Meeting](/wp-content/uploads/2020/04/BPTH_AACR_2020.pdf)\n\n[March 11, 2020Bio-Path Holdings Appoints Ernst & Young as New Auditor](/wp-content/uploads/2020/03/BPTH_EY-Release-20200311.pdf)\n\n[March 5, 2020BIO-PATH HOLDINGS REPORTS FULL YEAR 2019 FINANCIAL RESULTS](/wp-content/uploads/2020/03/BPTH_Year_End_2019_Earnings.pdf)\n\n[February 28, 2020Bio-Path Holdings to Announce Fourth Quarter and Full Year 2019 Financial Results on March 6, 2020](/wp-content/uploads/2020/02/BPTH_FY_4Q19_Earnings_Announcement.pdf)\n\n[January 8, 2020Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook](/wp-content/uploads/2020/01/BPTH_2020_Business_Outlook.pdf)\n\n[November 26, 2019BIO-PATH HOLDINGS ANNOUNCES SUCCESSFUL COMPLETION OF SAFETY TESTING IN STAGE 2 OF PHASE 2 CLINICAL TRIAL IN ACUTE MYELOID LEUKEMIA](/wp-content/uploads/2019/11/BPTH_pr_20191126.pdf)\n\n[November 25, 2019Bio-Path Holdings Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market](/wp-content/uploads/2019/12/BPTH_PressRelease_Nov_2019_RDO_Closing.pdf)\n\n[November 21, 2019Bio-Path Holdings Announces $8.0 Million Registered Direct Offering Priced At-the-Market](/wp-content/uploads/2019/12/BPTH_PressRelease_Nov_2019-RDO_Pricing.pdf)\n\n[November 21, 2019BIO-PATH HOLDINGS ANNOUNCES CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR BP1002](/wp-content/uploads/2019/11/BP1002_IND.pdf)\n\n[November 15, 2019BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS](/wp-content/uploads/2019/11/BPTH_3Q19_Earnings_Release.pdf)\n\n[November 8, 2019Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019](/wp-content/uploads/2019/11/BPTH_3Q_19_Earnings_Announcement.pdf)\n\n[October 15, 2019Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors](/wp-content/uploads/2019/10/BPTH_Martina_Molsbergen_PR.pdf)\n\n[September 25, 2019Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent](/wp-content/uploads/2019/09/Second_Platform_Patent_Issued.pdf)\n\n[September 3, 2019Bio-Path Holdings to Present at the H.C. Wainwright 21st Annual Global Investment Conference](/wp-content/uploads/2019/09/HCW_Announcement-2.pdf)\n\n[August 26, 2019Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Acute Myeloid Leukemia Trial](/wp-content/uploads/2019/08/BPTH_Patient_Dosing_in_Amended_AML_Trial.pdf)\n\n[August 15, 2019BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS](/wp-content/uploads/2019/08/BPTH-2Q19-Earnings-Release.pdf)\n\n[August 8, 2019Bio-Path Holdings to Announce Second Quarter 2019 Financial Results on August 15, 2019](/wp-content/uploads/2019/08/BPTH-2Q19_Earnings_Announcement-1.pdf)\n\n[May 16, 2019BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS](/wp-content/uploads/2019/05/BPTH_1Q19_Earnings_Release.pdf)\n\n[May 9, 2019Bio-Path Holdings to Announce First Quarter 2019 Financial Results on May 16, 2019](/wp-content/uploads/2019/05/BPTH_1Q19_Earnings_Announcement.pdf)\n\n[April 3, 2019Bio-Path Holdings Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2019 — Highlighting Important Cancer Gene, STAT3, Therapeutic Strategy in Pancreatic, Non-Small Cell Lung Cancers and Acute Myelogenous Leukemia](/wp-content/uploads/2019/04/BPTH_AACR_Poster_Presentation_Final.pdf)\n\n[March 20, 2019BIO-PATH HOLDINGS REPORTS FULL YEAR 2018 FINANCIAL RESULTS: Conference Call to be Held Today at 8:30 a.m. ET](/wp-content/uploads/2019/03/BPTH_4Q_and_FY_2018_Earnings_Release.pdf)\n\n[March 15, 2019Bio-Path Holdings to Announce Fourth Quarter and Full Year 2018 Financial Results on March 20, 2019](/wp-content/uploads/2019/03/BPTH_PR_2019_03_15-1.pdf)\n\n[March 14, 2019Bio-Bio-Path Holdings, Inc. Announces Closing of $18.5 Million Registered Direct Offering of Common Stock](/wp-content/uploads/2019/03/BPTH_PR_2019_03_14.pdf)\n\n[March 12, 2019Bio-Path Holdings, Inc. Announces $18.5 Million Registered Direct Offering of Common Stock](/wp-content/uploads/2019/03/BPTH_PR_2019_03_12.pdf)\n\n[March 6, 2019Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia](/wp-content/uploads/2019/03/BPTH_Press_Release_20190306.pdf)\n\n[February 28, 2019Bio-Path Holdings to Present Data at the 2019 AACR Annual Meeting](/wp-content/uploads/2019/02/BPTH_AACR_Release_20190228.pdf)\n\n[January 23, 2019Bio-Path Holdings, Inc. Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market](/wp-content/uploads/2019/01/BPTH_Closing_Press_Release_20190123.pdf)\n\n[January 18, 2019Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering Priced At-the-Market](/wp-content/uploads/2019/01/BPTH_Intraday_Registered_Direct_Pricing_Release.pdf)\n\n[January 18, 2019Bio-Path Holdings Announces 1-for-20 Reverse Stock Split](/wp-content/uploads/2019/01/BPTH_PR_Reverse_Stock_Split.pdf)\n\n[January 17, 2019Bio-Path Holdings, Inc. Announces Closing of Public Offering of Common Stock](/wp-content/uploads/2019/01/BPTH_Bio-Path_Announces_Closing_of_Public_Offering_of_Common_Stock.pdf)\n\n[January 15, 2019Bio-Path Holdings, Inc. Announces Pricing of Public Offering of Common Stock (Pricing)](/wp-content/uploads/2019/01/BPTH_2019_Underwritten_Takedown-Pricing.pdf)\n\n[January 15, 2019Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock (Launch)](/wp-content/uploads/2019/01/BPTH_2019_Underwritten_Takedown-Launch.pdf)\n\n[December 27, 2018Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook](/wp-content/uploads/2018/12/BPTH_2019_Business_Outlook.pdf)\n\n[December 3, 2018Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting](/wp-content/uploads/2018/12/BPTH_ASH_Release_2018.pdf)\n\n[November 15, 2018BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS](/wp-content/uploads/2018/11/BPTH_3Q18_Earnings_Release-1.pdf)\n\n[November 8, 2018Bio-Path Holdings to Announce Third Quarter 2018 Financial Results on November 15, 2018](/wp-content/uploads/2018/11/BPTH_3Q18_Earnings_Announcement.pdf)\n\n[November 1, 2018Bio-Path Holdings to Present Clinical Data at the 60th Annual American Society of Hematology Annual Meeting](/wp-content/uploads/2018/11/BPTH_ASH_Release_2018.pdf)\n\n[September 25, 2018Bio-Path Holdings, Inc. Announces Closing of $1.5 Million Registered Direct Offering](/wp-content/uploads/2018/09/BPTH_2018_Registered_Direct_Offering.pdf)\n\n[September 21, 2018Bio-Path Holdings, Inc. Announces $1.5 Million Registered Direct Offering](/wp-content/uploads/2018/09/BPTH-Press-Release-2018-Registered-Direct-Offering.pdf)\n\n[August 29, 2018Bio-Path Holdings to Present at the H.C. Wainwright 20th Annual Global Investment Conference](/wp-content/uploads/2018/08/BPTH_HCW_Announcement20180829.pdf)\n\n[August 27, 2018Bio-Path Holdings Announces First Patient Dosed in Expansion of Phase 2 Trial of Prexigebersen in Acute Myeloid Leukemia](/wp-content/uploads/2018/08/BPTH_AML_Expansion_Release.pdf)\n\n[August 16, 2018Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board](/wp-content/uploads/2018/08/BPTH_Fleming_SAB_Release.pdf)\n\n[August 15, 2018BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS](/wp-content/uploads/2018/08/BPTH-2Q18_Earnings_Release.pdf)\n\n[August 8, 2018Bio-Path Holdings to Announce Second Quarter 2018 Financial Results on August 15, 2018](/wp-content/uploads/2018/08/BPTH_2Q18_Earnings_Announcement.pdf)\n\n[May 16, 2018BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS](/wp-content/uploads/2018/05/BPTH_First_Qtr_2018_Earnings_Release-1.pdf)\n\n[May 10, 2018Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board](/wp-content/uploads/2018/05/BPTH_Anas_Younes_SAB.pdf)\n\n[May 9, 2018Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018](/wp-content/uploads/2018/05/BPTH_1Q18_Earnings_Announcement.pdf)\n\n[April 18, 2018Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting](/wp-content/uploads/2018/04/BPTH_AACR_Press.pdf)\n\n[April 3, 2018Bio-Path Holdings Announces Interim Data from Phase 2 Clinical Trial of Prexigebersen in Combination with Low Dose Cytarabine (LDAC) for the Treatment of Acute Myeloid Leukemia (AML)](/wp-content/uploads/2018/04/BPTH_Interim_Phase_2_AML_Data_Release.pdf)\n\n[April 3, 2018BIO-PATH HOLDINGS REPORTS FULL YEAR 2017 FINANCIAL RESULT](/wp-content/uploads/2018/04/BPTH_FY_2017_Earnings_Release.pdf)\n\n[March 29, 2018Bio-Path Holdings Announces Publication in The Lancet Haematology](/wp-content/uploads/2018/03/BPTH_Lancet_20180329.pdf)\n\n[March 27, 2018Bio-Path Holdings to Announce Fourth Quarter and Full Year 2017 Financial Results on April 3, 2018](/wp-content/uploads/2018/03/BPTH_4Q_and_FY_2017_Earnings_Announcement.pdf)\n\n[March 15, 2018Bio-Path Holdings to Present Data at the 2018 AACR Annual Meeting](/wp-content/uploads/2018/03/BPTH_AACR_2018.pdf)\n\n[March 6, 2018Bio-Path Holdings to Present at the 30th Annual ROTH Conference](/wp-content/uploads/2018/03/BPTH_ROTH2018.pdf)\n\n[February 9, 2018Bio-Path Holdings Announces 1-for-10 Reverse Stock Split](/wp-content/uploads/2018/02/BPTH_Reverse_Split_20180209.pdf)\n\n[February 5, 2018Bio-Path Holdings to Present at the BIO CEO & Investor Conference](/wp-content/uploads/2018/02/BPTH_BIO_CEO_20180205.pdf)\n\n[February 5, 2018Bio-Path Holdings Appoints Paul Aubert to its Board of Directors](/wp-content/uploads/2018/02/BPTH_BOD_Release_20180205.pdf)\n\n[December 29, 2017Bio-Path Holdings Provides Clinical Update and 2018 Business Outlook](/wp-content/uploads/2017/12/BPTH_Update_20171229.pdf)\n\n[November 9, 2017BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS](/wp-content/uploads/2017/11/BPTH_3Q17_Earnings_Release.pdf)\n\n[November 6, 2017Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts](/wp-content/uploads/2017/11/BPTH_Pipeline_Updates.pdf)\n\n[November 3, 2017Bio-Path Holdings, Inc. Announces $4 Million Registered Direct Offering](/wp-content/uploads/2017/11/BPTH_PR_2017_Registered_Direct_Offering.pdf)\n\n[November 3, 2017Bio-Path Holdings to Announce Third Quarter 2017 Financial Results on November 10, 2017](/wp-content/uploads/2017/11/BPTH_3Q17_Earnings_Announcement.pdf)\n\n[September 5, 2017Bio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference](/wp-content/uploads/2017/09/BPTH_Rodman_20170905.pdf)\n\n[August 10, 2017BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS](/wp-content/uploads/2017/08/BPTH_2Q17_Earnings_Release.pdf)\n\n[August 3, 2017Bio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017](/wp-content/uploads/2017/08/BPTH_2Q17_Earnings_Announcement.pdf)\n\n[July 19, 2017Bio-Path Holdings Receives Notice of Allowance for Key U.S. Composition of Matter Patent](/wp-content/uploads/2017/07/BPTH_PR_20170719.pdf)\n\n[July 17, 2017Bio-Path Holdings Appoints Mark Colonnese to its Board of Directors](/wp-content/uploads/2017/07/BPTH_BOD_Release.pdf)\n\n[June 20, 2017Stockholder Letter](/wp-content/uploads/2017/06/Stockholder_Letter_20170620.pdf)\n\n[May 11, 2017BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS](/wp-content/uploads/2017/05/BPTH_1Q17_Earnings_Release.pdf)\n\n[May 4, 2017Bio-Path Holdings to Announce First Quarter 2017 Financial Results on May 11, 2017](/wp-content/uploads/2017/05/BPTH_Earnings_Announce_1Q17.pdf)\n\n[April 17, 2017Bio-Path Holdings Announces Appointment of Dr. William Hahne as Vice President of Clinical Development](/wp-content/uploads/2017/04/Hahne-Press-Release-Final.pdf)\n\n[April 5, 2017Bio-Path Holdings Presents Results Showing Potential of BP1002 as Treatment for Aggressive Non-Hodgkin’s Lymphoma](/wp-content/uploads/2017/04/BPTH_NHL_data_AACR.pdf)\n\n[March 15, 2017BIO-PATH HOLDINGS REPORTS FULL YEAR 2016 FINANCIAL RESULTS](/wp-content/uploads/2017/03/BPTH_4Q16_Earnings_20170315.pdf)\n\n[March 14, 2017Bio-Path Holdings to Present at the Oppenheimer 27th Annual Healthcare Conference](/wp-content/uploads/2017/03/BPTH_Oppenheimer_Webcast.pdf)\n\n[March 13, 2017Bio-Path Holdings Announces Rescheduled Date and Time of Full Year 2016 Financial Results on March 15, 2017](/wp-content/uploads/2017/03/BPTH_Earnings-Announce_Rescheduled.pdf)\n\n[March 10, 2017Bio-Path Holdings to Present Data at the 2017 AACR Annual Meeting](/wp-content/uploads/2017/03/BPTH_AACR_20170310.pdf)\n\n[March 9, 2017Bio-Path Holdings to Announce Fourth Quarter and Full Year 2016 Financial Results on March 14, 2017](/wp-content/uploads/2017/03/BPTH_Earnings_Announce4Q16.pdf)\n\n[February 21, 2017Bio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory Board](/wp-content/uploads/2017/02/BPTH_Craig_Hooper_SAB_Release20170221.pdf)\n\n[February 7, 2017Bio-Path Holdings to Present at the 19th Annual BIO CEO & Investor Conference](/wp-content/uploads/2017/02/BPTH_to_Present_at_BIO_CEO_Conf_20170214.pdf)\n\n[December 6, 2016Bio-Path Holdings Presents Clinical Data Evaluating BP1001 as a Treatment for Chronic Myelogenous Leukemia at the 58th Annual American Society of Hematology Annual Meeting](/wp-content/uploads/2016/12/BPTH-ASH_poster_Final_20161201.pdf)\n\n[November 10, 2016BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS](/wp-content/uploads/2016/11/BPTH_3Q16_Earnings.pdf)\n\n[November 4, 2016BIO-PATH HOLDINGS TO ANNOUNCE THIRD QUARTER 2016 FINANCIAL RESULTS ON NOVEMBER 10, 2016](/wp-content/uploads/2016/11/BPTH_Earnings_Announcement_3Q16.pdf)\n\n[November 4, 2016Bio-Path Holdings to Present Data at the 2016 ASH Annual Meeting](/wp-content/uploads/2016/11/BPTH_ASH_Release20161104-1.pdf)\n\n[November 3, 2016Bio-Path Announces Orphan Drug Designation in the European Union for BP1001 for the Treatment of Acute Myeloid Leukemia](/wp-content/uploads/2016/11/BPTH_EU_Orphan_Drug_20161103.pdf)\n\n[November 2, 2016Bio-Path Holdings Announces First Patient Dosed in Phase 2 Trial Evaluating BP1001 in Acute Myeloid Leukemia](/wp-content/uploads/2016/11/BPTH_AML_FPD20161102.pdf)\n\n[September 6, 2016Bio-Path Holdings to Present at the Rodman & Renshaw 18th Annual Global Investment Conference](/wp-content/uploads/2016/09/BPTH_Rodman_20160906.pdf)\n\n[August 10, 2016BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS](/wp-content/uploads/2016/08/BPTH_2Q16_Earnings_Release.pdf)\n\n[August 3, 2016BIO-PATH HOLDINGS TO ANNOUNCE SECOND QUARTER 2016 FINANCIAL RESULTS ON AUGUST 10, 2016](/wp-content/uploads/2016/08/BPTH_EarnsAnnounce_20160803.pdf)\n\n[July 6, 2016Bio-Path Holdings to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference](/wp-content/uploads/2016/07/BPTH_Cantor_2016.pdf)\n\n[June 29, 2016Bio-Path Holdings, Inc. Announces $10 Million Registered Direct Offering](/wp-content/uploads/2016/06/BPTH_2016_Registered_Direct_Offering-1.pdf)\n\n[June 28, 2016Bio-Path Holdings Announces Collaboration With Thomas Jefferson University for Systemic Antisense Immunotherapy Treatment for Brain Cancer](/wp-content/uploads/2016/06/BPTH_TJU_PR_20160628.pdf)\n\n[June 20, 2016Bio-Path Holdings to Join Russell 3000® and Global Indexes](/wp-content/uploads/2016/06/BPTH_Russell_2016_06_20.pdf)\n\n[June 6, 2016Bio -Path Holdings Reports Promising Data from Phase I and Phase II Clinical Trials of BP1001 in Blood Cancers Presented at ASCO 2016](/wp-content/uploads/2016/06/BPTH_ASCO2016_Final.pdf)\n\n[May 19, 2016Bio-Path Holdings to Present Data at 2016 American Society of Clinical Oncology Annual Meeting](/wp-content/uploads/2016/05/BPTH_ASCO2016.pdf)\n\n[May 11, 2016Bio-Path Holdings Reports First Quarter 2016 Financial Results](/wp-content/uploads/2016/05/BPTH_PR_20160511.pdf)\n\n[May 5, 2016Bio-Path Holdings to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutic Conference](/wp-content/uploads/2016/05/BPTH_TIDES_20160505-2.pdf)\n\n[May 4, 2016Bio-Path Holdings to Announce First Quarter 2016 Financial Results on May 11, 2016](/wp-content/uploads/2016/05/BPTH_Earnings_20160504.pdf)\n\n[March 23, 2016Bio-Path Holdings Announces Research Collaboration on Autoimmune Indication with The University of Texas Southwestern Medical Center](/wp-content/uploads/2016/05/BPTH_UTSW_collaboration.pdf)\n\n[March 15, 2016Bio-Path Holdings Reports Fiscal Year 2015 Operational and Financial Results](/wp-content/uploads/2016/05/BPTH_FY_2015.pdf)\n\n[March 8, 2016Bio-Path Holdings Announces Pancreatic Cancer Research Collaboration with Leading Oncology Institution](/wp-content/uploads/2016/05/BPTH_MDACC_pancreatic20160308.pdf)\n\n[March 7, 2016Bio-Path Holdings to Present at the 28th Annual ROTH Conference on Monday, March 14 at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time)](/wp-content/uploads/2016/05/BPTH_ROTH_Conf_20160307.pdf)\n\n[March 3, 2016Bio-Path Holdings Announces Completion of the Safety Segment of the Phase II Clinical Trial of BP1001 in Acute Myeloid Leukemia](/wp-content/uploads/2016/05/BPTH-BP1001_cohort_8_completion-1.pdf)\n\n[January 6, 2016Bio-Path Holdings to Present at Biotech Showcase™ 2016](/wp-content/uploads/2016/05/BPTH_Biotech_Showcase_2016.pdf)\n\n[December 8, 2015Bio-Path Holdings’ Data from Phase I and Safety Segment of Phase II Clinical Trials in Blood Cancers Presented at 57th American Society of Hematology (ASH) Annual Meeting](/wp-content/uploads/2016/05/BPTH-ASH-2015_PR.pdf)\n\n[November 10, 2015Bio-Path Holdings Reports Third Quarter 2015 Operational and Financial Results](/wp-content/uploads/2016/05/BPTH_Q3_PR20151110.pdf)\n\n[November 5, 2015Bio-Path Holdings’ Data to be Presented at 57th American Society of Hematology (ASH) Annual Meeting](/wp-content/uploads/2016/05/BPTH_ASH_PR2015.pdf)\n\n[October 13, 2015Bio-Path Holdings to Present at the 14th Annual BIO Investor Forum](/wp-content/uploads/2016/05/BIO_Investor_Forum20151013.pdf)\n\n[October 9, 2015Bio-Path Holdings Announces Successful Completion of Cohort 7 of Phase Ib of Clinical Trial Evaluating Liposomal Grb-2 in Acute Myeloid Leukemia](/wp-content/uploads/2016/05/BPTH_Cohort_7_complete.pdf)\n\n[September 2, 2015Bio-Path Holdings To Present at the 17th Annual Rodman & Renshaw Global Investment Conference](/wp-content/uploads/2016/05/BPTH_Rodman_Renshaw2015.pdf)\n\n[August 31, 2015Bio-Path Holdings Forms Scientific Advisory Board to Support Advancement of Liposomal Grb-2 in Blood Cancers](/wp-content/uploads/2016/05/BPTH_SAB_Announcement.pdf)\n\n[August 11, 2015Bio-Path Holdings Reports Second Quarter 2015 Operational and Financial Results](/wp-content/uploads/2016/05/BPTH-Earnings_2Q15.pdf)\n\n[June 25, 2015Bio-Path Holdings Announces “At the Market” Offering with Cantor Fitzgerald](/wp-content/uploads/2016/05/ATM_with_Cantor_20150625.pdf)\n\n[May 12, 2015Bio-Path Holdings Reports First Quarter 2015 Operational and Financial Results](/wp-content/uploads/2016/05/Bpth1Q2015Results.pdf)\n\n[April 28, 2015Bio-Path Holdings Granted Orphan Drug Designation for Liposomal Grb-2 in Acute Myeloid Leukemia](/wp-content/uploads/2016/05/ODD_for_AML20150428.pdf)\n\n[April 24, 2015Letter to Shareholder from President and CEO](/wp-content/uploads/2016/05/BPTH_sh_-letter20150424.pdf)\n\n[April 22, 2015Bio-Path Holdings’ Drug Delivery Technology to be Featured in a Presentation at IBC’s 17th Annual TIDES Oligoneucleotide and Peptide Therapeutics Conference](/wp-content/uploads/2016/05/PR_TIDES_Conf_pres.pdf)\n\n[March 17, 2015Bio-Path Holdings Reports Fiscal Year 2014 Operational and Financial Results](/wp-content/uploads/2016/05/PR_4Q20150317.pdf)\n\n[March 5, 2015Letter to Shareholder from President and CEO](/wp-content/uploads/2016/05/Letter_Bpth.pdf)\n\n[February 9, 2015Bio-Path Holdings Starts Phase II Study with Liposomal Grb-2 in AML Patients](/wp-content/uploads/2016/05/Phase_II_starts.pdf)\n\n[January 7, 2015Bio-Path Holdings’ Liposomal Grb-2 Featured in Peer-Reviewed Journal “Expert Opinion on Drug Delivery”](/wp-content/uploads/2016/05/PeerExpertOpinion20150107.pdf)\n\n[January 6, 2015Bio-Path Holdings to Present at the Biotech Showcase 2015 Conference in San Francisco, CA on Tuesday, January 13, 2015 at 3:30 p.m. Pacific Time](/wp-content/uploads/2016/05/BiotechShowcaseAlert01132015.pdf)\n\n[December 22, 2014Bio-Path Holdings to Initiate Development of Liposomal Bcl-2 in Follicular Lymphoma – Company Broadening its Pipeline with Second Product Candidate –](/wp-content/uploads/2016/05/Bio_Path_Initiates_Devel_Liposomal_Bcl_2.pdf)\n\n[November 17, 2014Bio-Path Holdings Reports Third Quarter 2014 Operational and Financial Results](/wp-content/uploads/2016/05/3Q_20141117.pdf)\n\n[November 6, 2014Bio-Path Holdings Appoints Amy P. Sing, M.D. to its Board of Directors](/wp-content/uploads/2016/05/A_Sing_to_board110614.pdf)\n\n[October 16, 2014NASDAQ Release: Bio-Path Holdings, Inc. to Ring The NASDAQ Stock Market Closing Bell (Friday, October 17, 2014 at 3:45 – 4:00 PM Eastern Time)](/wp-content/uploads/2016/05/Nasdaq_bell_release_10_14.pdf)\n\n[October 7, 2014Bio-Path Holdings Successfully Completes Cohort 6 of Phase I Clinical Trial Evaluating Liposomal Grb-2 in Blood Cancers](/wp-content/uploads/2016/05/PR_Cohort_6_complete.pdf)\n\n[September 30, 2014Bio-Path Holdings to Present at the 13th Annual BIO Investor Forum in San Francisco on Tuesday October 7, 2014 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time)](/wp-content/uploads/2016/05/BioPath_Holdings_to_present_at_13th_Bio_Investor_Forum.pdf)\n\n[August 18, 2014Bio-Path Holdings Reports Second Quarter 2014 Operational and Financial Results](/wp-content/uploads/2016/05/2Q_14_final.pdf)\n\n[June 30, 2014Bio-Path Holdings Added to Russell Global, Russell 3000 and Russell Microcap Indexes](/wp-content/uploads/2016/05/RussellIndex_20140630.pdf)\n\n[June 19, 2014Enrollment Continues Into Bio-Path Holdings Phase I Clinical Trial](/wp-content/uploads/2016/05/Enrollment_continues_In_Phase1.pdf)\n\n[May 19, 2014Bio-Path Holdings Reports First Quarter 2014 Operational and Financial Results](/wp-content/uploads/2016/05/PR_1Q14.pdf)\n\n[April 1, 2014Bio-Path Holdings Reports Fiscal Year 2013 Operational and Financial Results](/wp-content/uploads/2016/05/PR_2013_Earnings_Release.pdf)\n\n[March 26, 2014Bio-Path Holdings, Inc. Appoints Ulrich M. Mueller Chief Operating Officer](/wp-content/uploads/2016/05/PR_BPTH_COOappt03_26_14.pdf)\n\n[March 5, 2014Bio-Path Holdings Announces Uplisting to the NASDAQ Capital Market](/wp-content/uploads/2016/05/PR_BPTHUplisting_to_Nasdaq.pdf)\n\n[January 16, 2014Bio-Path Holdings, Inc. to Raise $10 Million in Registered Direct Offering](/wp-content/uploads/2016/05/BPTH_to_Raise_10_mil_2014_01_16.pdf)\n\n[January 7, 2014Bio-Path Holdings to Present at the Biotech Showcase 2014 Conference in San Francisco, CA on Wednesday, January 15, 2014 at 8:00 a.m. Pacific Time](/wp-content/uploads/2016/05/PR_Biotech_Showcase_2014.pdf)\n\n[December 9, 2013Preliminary Results from Bio-Path Holdings’ Phase I Clinical Trial Presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans](/wp-content/uploads/2016/05/ASH_Meeting_Poster_Presentation_Dec2013.pdf)\n\n[November 15, 2013Bio-Path Holdings Reports Third Quarter 2013 Operational and Financial Results](/wp-content/uploads/2016/05/PR_Third_Quarter_2013_Earnings.pdf)\n\n[November 7, 2013Data from Bio-Path Holdings Phase I Clinical Trial in Hematological Cancers to be Presented at American Society of Hematology Annual Meeting: Data Suggests Potential for AML and MDS Disease Inhibition with Liposomal Grb-2-](/wp-content/uploads/2016/05/BPTH_PR_Presentation_at_ASH_Annual_Meeting.pdf)\n\n[October 1, 2013Bio-Path Holdings to Present at the 12th Annual BIO Investor Forum](/wp-content/uploads/2016/05/PR_Bio_Path_To_Present_at_Bio_Investor_Forum.pdf)\n\n[September 19, 2013Bio-Path Holdings, Inc. Retains Investment Banking Firm Maxim Group LLC](/wp-content/uploads/2016/05/Bio-PathRetainsInvestmentBankingFirmMaximGroupLLC.pdf)\n\n[August 15, 2013Bio-Path Holdings Reports Second Quarter 2013 Operational and Financial Results](/wp-content/uploads/2016/05/PR_BPTH_Second_Quarter_2013_Earnings_Release.pdf)\n\n[August 9, 2013Bio-Path Holdings’ Liposomal Delivery Technology Achieves Major Milestone in development of Antisense Therapeutics](/wp-content/uploads/2016/05/Bio_Path_Delivery_Technology_Major_Milestone.pdf)\n\n[July 22, 2013Bio-Path Holdings Initiates Development of Liposomal Grb-2 for Triple Negative and Inflammatory Breast Cancers](/wp-content/uploads/2016/05/Testing_initiated_in_TNBC_IBC.pdf)\n\n[June 6, 2013Bio-Path Holdings Successfully Completes Fifty Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia](/wp-content/uploads/2016/05/PR_Fifth_Cohort_Complete_June_2013.pdf)\n\n[May 16, 2013Bio-Path Holdings Reports First Quarter 2013 Operational and Financial Results](/wp-content/uploads/2016/05/PR_bpth_First_Qtr_2013_Earnings_Release.pdf)\n\n[April 2, 2013Bio-Path Holdings Reports Fiscal Year 2012 Operational and Financial Results](/wp-content/uploads/2016/05/PR_2012_Earnings_Release.pdf)\n\n[March 7, 2013Bio-Path Holdings Begins Enrollment in Fifth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias](/wp-content/uploads/2016/05/PR_Fifth_Cohort20130307.pdf)\n\n[January 3, 2013Bio-Path Holdings to Present at Biotech Showcase 2013 Conference in San Francisco, California on Tuesday, January 8, 2013 at 11:00 am Pacific Time](/wp-content/uploads/2016/05/PR_Presentation_at_Biotech_Showcase_2013_Conference.pdf)\n\n[December 6, 2012Bio-Path Holdings to Expand Development of Liposomal Grb-2 into two additional indications: Triple Negative and Inflammatory Breast Cancers](/wp-content/uploads/2016/05/Development_of_Liposoma_Grb-2_for_TNBC_and_IBC_final_12_6_12.pdf)\n\n[November 16, 2012Bio-Path Holdings Reports Third Quarter 2012 Operational and Financial Results](/wp-content/uploads/2016/05/PR_BPTH_2012_3RD_QTR_Op_Results.pdf)\n\n[November 14, 2012Bio-Path Holdings Successfully Completes Fourth Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia](/wp-content/uploads/2016/05/Press_release_re_4th_Cohort_and_Earnings_Release.pdf)\n\n[October 4, 2012Bio-Path Holdings Adds New Board Member](/wp-content/uploads/2016/05/PR_BioPath_Adds_Board_Member_10_4_12.pdf)\n\n[October 3, 2012Bio-Path Holdings to Present at the 11th Annual Bio Investor Forum Conference in San Francisco on Wednesday Oct 10, 2012 at 11:30 am Pacific Time (2:30 pm Eastern Time)](/wp-content/uploads/2016/05/PR_Bio_Investor_Forum_10_12.pdf)\n\n[September 4, 2012Bio-Path Holdings to Present at the Rodman & Renshaw Annual Global Investment Conference](/wp-content/uploads/2016/05/PR_2012_09_04_Rodman__Renshaw.pdf)\n\n[August 16, 2012Bio-Path Holdings Reports Second Quarter 2012 Operational and Financial Results](/wp-content/uploads/2016/05/PRBPTH_20120816.pdf)\n\n[July 25, 2012Bio-Path Holdings Begins Enrollment in Fourth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias](/wp-content/uploads/2016/05/PR_start_of_cohort4_7_25_12.pdf)\n\n[June 4, 2012Bio-Path Holdings Shares Commence Trading On OTCQX, The Top Tier Of The OTC Market](/wp-content/uploads/2016/05/PR_2012_06_04.pdf)\n\n[May 29, 2012Bio-Path Holdings Successfully Completes Third Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia](/wp-content/uploads/2016/05/PR_Third_cohort_5_29_12.pdf)\n\n[May 17, 2012Bio-Path Holdings Reports First Quarter 2012 Operational and Financial Results – Quarter Highlighted by Progress with Lead Product Candidate, Liposomal Grb-2](/wp-content/uploads/2016/05/PR_1Q12_5_17_12.pdf)\n\n[April 3, 2012Bio-Path Holdings Reports Fiscal Year 2011 Operational and Financial Results](/wp-content/uploads/2016/05/PR_BPTH_20120403YrEndFinancialResults.pdf)\n\n[March 29, 2012Bio-Path Holdings Engages PondelWilkinson for Retailer Investor Relations Program](/wp-content/uploads/2016/05/PR_BPTH_20120329PondelWilkinson.pdf)\n\n[February 7, 2012Bio-Path Holdings Successfully Completes Second Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia](/wp-content/uploads/2016/05/PR20120207-.pdf)\n\n[January 4, 2012Bio-Path Holdings to Present at Biotech Showcase 2012 Conference](/wp-content/uploads/2016/05/PR_Bpth_2012_01_04.pdf)\n\n[December 13, 2011Bio-Path Holdings’ Initial Phase I Data in Leukemia Clinical Trial Demonstrates that Its Neutral Lipid Delivery Technology Antisense Drug BP-101-100-1.01 (Liposomal Grb-2) Is Well Tolerated with Activity Seen at Low-Starting Dose](/wp-content/uploads/2016/05/PR_Data_from_Phase_I_Clinical_Trial_Presented.pdf)\n\n[November 15, 2011Press Release Form 8-K – 3rd Quarter Financial Results](/wp-content/uploads/2016/05/PR_Fiscal_3Q_11_Results.pdf)\n\n[October 24, 2011Proxy Statement fothereer 2011](/wp-content/uploads/2016/05/Proxy_2011.pdf)\n\n[October 19, 2011Bio-Path Holdings to Present at the 10th Annual BIO Investors Forum Conference in San Francisco on Wednesday, October 26, 2011. Link to Conference at 3:00pm Pacific Time](/wp-content/uploads/2016/05/PR_Bio_Investor_Forum.pdf)\n\n[October 4, 2011Initial Data from Bio-Path Holdings’ Phase I Clinical Trial Accepted for Presentation at American Society ofHematology Annual Meeting](/wp-content/uploads/2016/05/PR_BPTH_2011_10_04.pdf)\n\n[September 6, 2011Bio-Path Holdings to Present at the Rodman & RenshawAnnual Global Investment Conference](/wp-content/uploads/2016/05/BPTH-Rodman-Conf-Alert-2011-09-06.pdf)\n\n[August 11, 2011First Cohort Successfully Completed in Bio-Path Holding’s Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia](/wp-content/uploads/2016/05/First-cohort-complete-of-Phase-I-study.pdf)\n\n[July 27, 2011Bio-Path recently featured in Genomeweb/Gene Silencing News](/wp-content/uploads/2016/05/GeneSilencing_072111.pdf)\n\n[May 17, 2011Bio-Path Holdings Reports First Quarter 2011 Financial Results](/wp-content/uploads/2016/05/PRBpth2011FirstQtrFinancialResults.pdf)\n\n[April 28, 2011Bio-Path Holdings Appoints Dr. Ana M. Tari Director, Preclinical Operations and Research](/wp-content/uploads/2016/05/Bpth-Dr-Tari-Appointment-1.pdf)\n\n[April 4, 2011Zack’s Small-Cap Research Release](/wp-content/uploads/2016/05/BPTH_SCIR-2011-4-4.pdf)\n\n[March 31, 2011Bio-Path Holdings Reports Fiscal Year 2010 Operation and Financial Results](/wp-content/uploads/2016/05/PR_Fiscal-Year-2010-Results.pdf)\n\n[February 23, 2011Zack’s Small-Cap Research Release](/wp-content/uploads/2016/05/BPTH_SCIR-2011-2-23.pdf)\n\n[February 23, 2011CEOCFO Interviews Peter H. Nielsen, CEO](/wp-content/uploads/2016/05/CEOCFOInterview.pdf)\n\n[November 15, 2010Bio-Path Holdings Reports Third Quarter 2010 Financial Results](/wp-content/uploads/2016/05/PRl10QResultsNov2010.pdf)\n\n[November 3, 2010Bio-Path Holdings Awarded Grant From The U.S. Government’s Qualifying Therapeutic Discovery Project Program](/wp-content/uploads/2016/05/Therapeutic-Grant-Program-Grant-Nov-2010.pdf)\n\n[August 17, 2010Bio-Path Holdings Reports Fiscal 2010 Second Quarter Financial Results Company Also Completes Initial Sale of Registered Shares Under Financing With Lincoln Park Capital](/wp-content/uploads/2016/05/PR_08_17_2010.pdf)\n\n[July 29, 2010Bio-Path Holdings announces Dosing of First Patient in a Phase I Clinical Trial of its Liposomal Grb-2 Cancer Drug Candidate](/wp-content/uploads/2016/05/PR_20100729DosingOfFirstPatient.pdf)\n\n[June 4, 2010Bio-Path Holdings Signs Equity Financing Deal Equity Purchase Agreement With Institutional Investor Lincoln Park Capital to Provide Up to $7 Million In New Capital](/wp-content/uploads/2016/05/PR060410LincolnParkEquityFinancing.pdf)\n\n[March 12, 2010FDA Allows IND For Bio-Path Holdings’ Liposomal Grb-2 Company to Commence Phase I Clinical Trial Of Its Cancer Drug To Treat CML, AML, ALL, & MDS](/wp-content/uploads/2016/05/PRBioPathINDRelease2010.pdf)\n\n[December 14, 2009Bio-Path Holdings, Inc. Completes Private Placement Capital Raise and Provides Update to IND Status](/wp-content/uploads/2016/05/PRBPCompletesCapRaise12142009.pdf)\n\n[November 2, 2009Bio-Path Holdings, Inc. Operations Update](/wp-content/uploads/2016/05/PROperationsUpdate11022009.pdf)\n\n[September 22, 2009Bio-Path Holdings, Inc. Announces Plans To Develop Liposome Tumor Targeting Technology Licensed from The University of Texas M. D. Anderson Cancer Center](/wp-content/uploads/2016/05/BPTHPR092109.pdf)\n\n[July 23, 2009Bio-Path Holdings, Inc. Provides Operations Update and Overview Of New Targeting Technology](/wp-content/uploads/2016/05/PRBPTH20090623.pdf)\n\n[June 6, 2009Proxy](/wp-content/uploads/2016/05/Proxy_BPTH.pdf)\n\n[June 6, 2009Proxy Statement](/wp-content/uploads/2016/05/Proxy_Statement_BPTH.pdf)\n\n[April 14, 2009Bio-Path Holdings, Inc. Announces Clinical Support Agreement With ACORN And Names Bradley G. Somer, M.D., As Medical Officer For Phase I Clinical Trial](/wp-content/uploads/2016/05/BPTHAnnouncesClinicalAgreementandMedicalOfficer.pdf)\n\n[December 10, 2008Letter To Shareholders](/wp-content/uploads/2016/05/LetterToShareholders_120908.pdf)\n\n[December 3, 2008Bio-Path Holdings, Inc. Retains Alliance Advisors, LLC to Implement Investor Relations Program](/wp-content/uploads/2016/05/BPTHPR3.pdf)\n\n[November 17, 2008Bio-Path Holdings, Inc. Announces the Signing of a Drug Manufacturing Agreement with Althea Technologies, Inc.](/wp-content/uploads/2016/05/PRAlthea.pdf)\n\n[March 3, 2008Bio-Path Becomes a Publicly Traded Company](/wp-content/uploads/2016/05/BPTH-PR1.pdf)\n\n[![logo](https://biopath.wpengine.com/wp-content/uploads/2021/09/BPTHlogo.png)](/)\n\n  * [About Bio-Path](https://www.biopathholdings.com/about/)\n    * [Overview](https://www.biopathholdings.com/about/)\n    * [Leadership](https://www.biopathholdings.com/about/leadership/)\n    * [Board of Directors](https://www.biopathholdings.com/about/board-of-directors/)\n    * [Scientific Advisory Board](https://www.biopathholdings.com/about/scientific-advisory-board/)\n    * [Partnering Opportunities](https://www.biopathholdings.com/about/partnering-opportunities/)\n  * [Technology](https://www.biopathholdings.com/technology/)\n  * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Prexigebersen](https://www.biopathholdings.com/pipeline/prexigebersen/)\n    * [BP1001-A](https://www.biopathholdings.com/pipeline/bp1001-a/)\n    * [BP1002](https://www.biopathholdings.com/pipeline/bp1002/)\n    * [BP1003](https://www.biopathholdings.com/pipeline/bp1003/)\n  * [Patients](https://www.biopathholdings.com/patients/)\n  * [Investors](https://www.biopathholdings.com/investors/)\n    * [Overview](https://www.biopathholdings.com/investors/)\n    * [SEC Filings](https://www.biopathholdings.com/investors/sec-filings/)\n    * [Corporate Governance](https://www.biopathholdings.com/investors/corporate-governance/)\n  * [Media](https://www.biopathholdings.com/media/)\n    * [Press Releases](https://www.biopathholdings.com/media/)\n    * [Events](https://www.biopathholdings.com/media/events/)\n    * [Presentations & Publications](https://www.biopathholdings.com/media/presentations-publications/)\n  * [Careers](https://www.biopathholdings.com/careers/)\n  * [Contact Us](https://www.biopathholdings.com/contact-us/)\n\n\n"
        }
      ]
    },
    {
      "section_name": "Events",
      "links": [
        {
          "title": "Events",
          "url": "https://www.biopathholdings.com/media/events/",
          "content": "[![Bio-Path Holdings](/wp-content/uploads/2021/09/BPTHlogo.png)](https://www.biopathholdings.com/)\n\n  * [About Bio-Path](https://www.biopathholdings.com/about/)\n    * [Overview](https://www.biopathholdings.com/about/)\n    * [Leadership](https://www.biopathholdings.com/about/leadership/)\n    * [Board of Directors](https://www.biopathholdings.com/about/board-of-directors/)\n    * [Scientific Advisory Board](https://www.biopathholdings.com/about/scientific-advisory-board/)\n    * [Partnering Opportunities](https://www.biopathholdings.com/about/partnering-opportunities/)\n  * [Technology](https://www.biopathholdings.com/technology/)\n  * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Prexigebersen](https://www.biopathholdings.com/pipeline/prexigebersen/)\n    * [BP1001-A](https://www.biopathholdings.com/pipeline/bp1001-a/)\n    * [BP1002](https://www.biopathholdings.com/pipeline/bp1002/)\n    * [BP1003](https://www.biopathholdings.com/pipeline/bp1003/)\n  * [Patients](https://www.biopathholdings.com/patients/)\n  * [Investors](https://www.biopathholdings.com/investors/)\n    * [Overview](https://www.biopathholdings.com/investors/)\n    * [SEC Filings](https://www.biopathholdings.com/investors/sec-filings/)\n    * [Corporate Governance](https://www.biopathholdings.com/investors/corporate-governance/)\n  * [Media](https://www.biopathholdings.com/media/)\n    * [Press Releases](https://www.biopathholdings.com/media/)\n    * [Events](https://www.biopathholdings.com/media/events/)\n    * [Presentations & Publications](https://www.biopathholdings.com/media/presentations-publications/)\n  * [Careers](https://www.biopathholdings.com/careers/)\n  * [Contact Us](https://www.biopathholdings.com/contact-us/)\n\n\n\n[November 15, 2023Webcast Link to Third Quarter 2023 Financial Results Conference Call on Wednesday, November 15, 2023 at 8:30 a.m. ET](https://edge.media-server.com/mmc/p/v6zym4vs)\n\n[October 24, 2023Webcast Link to Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia – October 30, 2023 at 9:00 a.m. ET](https://edge.media-server.com/mmc/p/pho7axxk)\n\n[September 10, 2023Webcast Link to H.C. Wainwright 25th Annual Global Investment Conference – Tuesday. September 12, 2023](https://journey.ct.events/view/27e24ea7-6147-4283-9d8a-b008bdc48363)\n\n[August 15, 2023Webcast link to Second Quarter 2023 Financial Results Conference Call – Tuesday August 15, 2023 at 8:30 a.m. ET]( https://edge.media-server.com/mmc/p/zibcsm24)\n\n[September 6, 2022Webcast link to H.C. Wainwright 24th Annual Global Investment Conference – Monday, September 12, 2022 at 7:00 am ET](https://journey.ct.events/view/35bd1313-d071-4ae1-b622-d7f8869d4d08)\n\n[March 4, 2022Webcast Link to 2021 Full Year Earnings Financial Results Conference Call – Friday, March 11, 2022 at 8:30 a.m. ET](https://edge.media-server.com/mmc/p/cqhxqhse)\n\n[January 5, 2022Webcast Link to Bio-Path Holdings to H.C. Wainwright Presentation – Monday, January 10, 2022 at 7:00 a.m. ET]()\n\n[August 13, 2021Webcast Link to 2021 Second Quarter Earnings Financial Results Conference Call – Friday, August 13, 2021 at 8:30 a.m. ET](https://edge.media-server.com/mmc/p/mcv7f5f4)\n\n[May 14, 2021Webcast Link to 2021 First Quarter Earnings Financial Results Conference Call – Friday, May 14, 2021 at 8:30 a.m. ET](https://edge.media-server.com/mmc/p/r6gw9ft2)\n\n[November 13, 2020Webcast Link to Third Quarter 2020 Financial Results Conference Call – Friday November 13, 2020 @ 8:30 a.m. ET](https://edge.media-server.com/mmc/p/gcphaaxs)\n\n[September 16, 2020Webcast Link to Bio-Path Holdings to H.C. Wainwright Presentation – Wednesday, September 16, 2020 at 11:30 a.m. ET](https://wsw.com/webcast/hcw7/bpth/1605854)\n\n[August 14, 2020Webcast Link to Second Quarter 2020 Financial Results Conference Call – Friday, August 14, 2020 at 8:30 a.m. ET](https://edge.media-server.com/mmc/p/vwjx5fc7)\n\n[May 15, 2020Webcast Link to First Quarter 2020 Financial Results Conference Call – Friday, May 15, 2020 at 8:30 a.m. ET](https://edge.media-server.com/mmc/p/hs2cpzaw)\n\n[March 10, 2020Webcast Link to 2020 Year End Earnings 2020 Financial Results Conference Call – Wednesday, March 10, 2021 at 8:30 a.m. ET](https://edge.media-server.com/mmc/p/87onpwdj)\n\n[![logo](https://biopath.wpengine.com/wp-content/uploads/2021/09/BPTHlogo.png)](/)\n\n  * [About Bio-Path](https://www.biopathholdings.com/about/)\n    * [Overview](https://www.biopathholdings.com/about/)\n    * [Leadership](https://www.biopathholdings.com/about/leadership/)\n    * [Board of Directors](https://www.biopathholdings.com/about/board-of-directors/)\n    * [Scientific Advisory Board](https://www.biopathholdings.com/about/scientific-advisory-board/)\n    * [Partnering Opportunities](https://www.biopathholdings.com/about/partnering-opportunities/)\n  * [Technology](https://www.biopathholdings.com/technology/)\n  * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Prexigebersen](https://www.biopathholdings.com/pipeline/prexigebersen/)\n    * [BP1001-A](https://www.biopathholdings.com/pipeline/bp1001-a/)\n    * [BP1002](https://www.biopathholdings.com/pipeline/bp1002/)\n    * [BP1003](https://www.biopathholdings.com/pipeline/bp1003/)\n  * [Patients](https://www.biopathholdings.com/patients/)\n  * [Investors](https://www.biopathholdings.com/investors/)\n    * [Overview](https://www.biopathholdings.com/investors/)\n    * [SEC Filings](https://www.biopathholdings.com/investors/sec-filings/)\n    * [Corporate Governance](https://www.biopathholdings.com/investors/corporate-governance/)\n  * [Media](https://www.biopathholdings.com/media/)\n    * [Press Releases](https://www.biopathholdings.com/media/)\n    * [Events](https://www.biopathholdings.com/media/events/)\n    * [Presentations & Publications](https://www.biopathholdings.com/media/presentations-publications/)\n  * [Careers](https://www.biopathholdings.com/careers/)\n  * [Contact Us](https://www.biopathholdings.com/contact-us/)\n\n\n"
        }
      ]
    },
    {
      "section_name": "Presentations & Publications",
      "links": [
        {
          "title": "Presentations & Publications",
          "url": "https://www.biopathholdings.com/media/presentations-publications/",
          "content": "[![Bio-Path Holdings](/wp-content/uploads/2021/09/BPTHlogo.png)](https://www.biopathholdings.com/)\n\n  * [About Bio-Path](https://www.biopathholdings.com/about/)\n    * [Overview](https://www.biopathholdings.com/about/)\n    * [Leadership](https://www.biopathholdings.com/about/leadership/)\n    * [Board of Directors](https://www.biopathholdings.com/about/board-of-directors/)\n    * [Scientific Advisory Board](https://www.biopathholdings.com/about/scientific-advisory-board/)\n    * [Partnering Opportunities](https://www.biopathholdings.com/about/partnering-opportunities/)\n  * [Technology](https://www.biopathholdings.com/technology/)\n  * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Prexigebersen](https://www.biopathholdings.com/pipeline/prexigebersen/)\n    * [BP1001-A](https://www.biopathholdings.com/pipeline/bp1001-a/)\n    * [BP1002](https://www.biopathholdings.com/pipeline/bp1002/)\n    * [BP1003](https://www.biopathholdings.com/pipeline/bp1003/)\n  * [Patients](https://www.biopathholdings.com/patients/)\n  * [Investors](https://www.biopathholdings.com/investors/)\n    * [Overview](https://www.biopathholdings.com/investors/)\n    * [SEC Filings](https://www.biopathholdings.com/investors/sec-filings/)\n    * [Corporate Governance](https://www.biopathholdings.com/investors/corporate-governance/)\n  * [Media](https://www.biopathholdings.com/media/)\n    * [Press Releases](https://www.biopathholdings.com/media/)\n    * [Events](https://www.biopathholdings.com/media/events/)\n    * [Presentations & Publications](https://www.biopathholdings.com/media/presentations-publications/)\n  * [Careers](https://www.biopathholdings.com/careers/)\n  * [Contact Us](https://www.biopathholdings.com/contact-us/)\n\n\n\n[November 8, 2024Webcast link to Third Quarter 2024 Financial Results Conference Call – Friday, November 15, 2024 at 8:30 a.m. ET](https://edge.media-server.com/mmc/p/qydznuam)\n\n[September 3, 2024Webcast link to the H.C. Wainwright 26th Annual Global Investment Conference – Monday, September 9, 2024 at 7:00 a.m. ET.](https://journey.ct.events/view/da47f4fa-1bca-4692-ba06-44530cf3ae02)\n\n[August 8, 2024Webcast link to Second Quarter 2024 Financial Results Conference Call – Thursday, August 15, 2024 at 8:30 a.m. ET](https://edge.media-server.com/mmc/p/9cu636fs)\n\n[May 9, 2024Webcast link to First Quarter 2024 Financial Results Conference Call – Wednesday, May 15, 2023 at 8:30 a.m. ET](https://edge.media-server.com/mmc/p/3cw6b85b)\n\n[March 1, 2024Webcast Link to Fourth Quarter and Full Year for period ended December 31, 2023 on Friday, March 8, 2024 at 8:30 a.m. ET](https://edge.media-server.com/mmc/p/xjjch2qr)\n\n[September 10, 2023Webcast Link to H.C. Wainwright 25th Annual Global Investment Conference – Tuesday. September 12, 2023](https://journey.ct.events/view/27e24ea7-6147-4283-9d8a-b008bdc48363)\n\n[May 5, 2023Webcast link to First Quarter 2023 Financial Results Conference Call – Friday, May 12. 2023 at 8:30 a.m. ET](https://edge.media-server.com/mmc/p/npjya4nu)\n\n[March 24, 2023Webcast link to Fourth Quarter and Full Year 2022 Financial Results Conference Call – Friday, March 31. 2023 at 8:30 a.m. ET](https://edge.media-server.com/mmc/p/9xjfzmid)\n\n[November 8, 2022Webcast Link to Third Quarter 2022 Earnings Financial Results Conference Call – Tuesday November 15, 2022 at 8:30 a.m. ET](https://nam12.safelinks.protection.outlook.com/?url=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2Fttxsd7n3&data=05%7C01%7CWill.OConnor%40sternir.com%7C04e57df8ae96485efc5e08daa15a5a81%7Cb71ff3f628164ca8a9b938f820f91ad1%7C0%7C0%7C637999706713982962%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=%2B4rSIsIPYT2iUKGgptCc20OhZLvFXS%2BjB2IKT2npJJM%3D&reserved=0)\n\n[September 6, 2022Webcast link to H.C. Wainwright 24th Annual Global Investment Conference – Monday, September 12, 2022 at 7:00 am ET](https://journey.ct.events/view/35bd1313-d071-4ae1-b622-d7f8869d4d08)\n\n[August 17, 2022H.C. Wainwright & Co. – August 17, 2022 – Article](https://hcwco.bluematrix.com/sellside/EmailDocViewer?encrypt=ff8fb8d6-8e4a-45bb-a014-92a7de2b21ea&mime=pdf&co=Hcwco&id=pnielsen@biopathholdings.com&source=mail)\n\n[August 13, 2022Webcast Link to Second Quarter 2022 Earnings Financial Results Conference Call – Tuesday, August 16, 2022 at 8:30 a.m. ET](https://edge.media-server.com/mmc/p/gs6nuq2w)\n\n[August 12, 2022Corporate Presentation May 2022](https://www.biopathholdings.com/wp-content/uploads/2022/08/Corporate-Presentation-May-2022.pdf)\n\n[May 10, 2022Webcast Link to First Quarter 2022 Earnings Financial Results Conference Call – Tuesday, May 17, 2022 at 8:30 a.m. ET](https://edge.media-server.com/mmc/p/784sdcnu)\n\n[April 14, 2022BP1003 AACR 2022 Abstract](https://www.biopathholdings.com/wp-content/uploads/2022/04/BP1003-AACR-2022-Abstract.pdf)\n\n[March 4, 2022Webcast Link to 2021 Full Year Earnings Financial Results Conference Call – Friday, March 11, 2022 at 8:30 a.m. ET](https://edge.media-server.com/mmc/p/cqhxqhse)\n\n[February 1, 2022Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2.](https://pubmed.ncbi.nlm.nih.gov/35056993/)\n\n[February 1, 2022The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery](https://pubmed.ncbi.nlm.nih.gov/33923688/)\n\n[December 21, 2020Annual Shareholders Presentation Slides – December 2020](/wp-content/uploads/2020/12/Annual_Shareholder_Meeting_Dec_2020.pdf)\n\n[December 6, 2019STONEGATE Capital Partners December 4, 2019 Report](http://stonegateinc.com/reports/BPTH%20DEC%202019.pdf)\n\n[December 2, 2019H.C. Wainwright / BPTH: Safety Testing of Phase 2 AML Trial Completed; Financing Closed; Reiterate Buy; Adjusting PT to $25](https://hcwco.bluematrix.com/sellside/EmailDocViewer?encrypt=35f17cbf-2281-4c21-9cd8-d6742ec31a6a&mime=pdf&co=Hcwco&id=pnielsen@biopathholdings.com&source=mail)\n\n[January 31, 2019Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) – January 2019](http://stonegateinc.com/reports/BPTH%20Update%20JAN%202019%20Final%20v3.pdf)\n\n[August 23, 2018Stonegate Capital Partners Research Report – August 2018](http://stonegateinc.com/reports/BPTH%20Update%20AUG%20Final%202018.pdf)\n\n[March 6, 2018BP1001 phase I-Ib protocol](/wp-content/uploads/2018/01/BP1001-phase-I-Ib-protocol.pdf)\n\n[March 2, 2018Drug Development and Delivery Published Article: DNA THERAPEUTICS – DNAbilize-ING Antisense](http://www.drug-dev.com/Main/Back-Issues/DNA-THERAPEUTICS-DNAbilizeING-Antisense-1445.aspx)\n\n[June 9, 2017Published Article: Evolution of Antisense Oligonucleotides in Oncology]()\n\n[June 28, 2016Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01]()\n\n[April 7, 2016OncLive interview with Dr. Cortes on BP-100.01 in Patients with Relapsed/Refractory AML]()\n\n[April 5, 2016Bio-Path Hopes to Blaze Profitable Path With Antisense Drugs – January 2016](/wp-content/uploads/2016/04/ATI_Biopath_1-25-16_000.pdf)\n\n[![logo](https://biopath.wpengine.com/wp-content/uploads/2021/09/BPTHlogo.png)](/)\n\n  * [About Bio-Path](https://www.biopathholdings.com/about/)\n    * [Overview](https://www.biopathholdings.com/about/)\n    * [Leadership](https://www.biopathholdings.com/about/leadership/)\n    * [Board of Directors](https://www.biopathholdings.com/about/board-of-directors/)\n    * [Scientific Advisory Board](https://www.biopathholdings.com/about/scientific-advisory-board/)\n    * [Partnering Opportunities](https://www.biopathholdings.com/about/partnering-opportunities/)\n  * [Technology](https://www.biopathholdings.com/technology/)\n  * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Pipeline](https://www.biopathholdings.com/pipeline/)\n    * [Prexigebersen](https://www.biopathholdings.com/pipeline/prexigebersen/)\n    * [BP1001-A](https://www.biopathholdings.com/pipeline/bp1001-a/)\n    * [BP1002](https://www.biopathholdings.com/pipeline/bp1002/)\n    * [BP1003](https://www.biopathholdings.com/pipeline/bp1003/)\n  * [Patients](https://www.biopathholdings.com/patients/)\n  * [Investors](https://www.biopathholdings.com/investors/)\n    * [Overview](https://www.biopathholdings.com/investors/)\n    * [SEC Filings](https://www.biopathholdings.com/investors/sec-filings/)\n    * [Corporate Governance](https://www.biopathholdings.com/investors/corporate-governance/)\n  * [Media](https://www.biopathholdings.com/media/)\n    * [Press Releases](https://www.biopathholdings.com/media/)\n    * [Events](https://www.biopathholdings.com/media/events/)\n    * [Presentations & Publications](https://www.biopathholdings.com/media/presentations-publications/)\n  * [Careers](https://www.biopathholdings.com/careers/)\n  * [Contact Us](https://www.biopathholdings.com/contact-us/)\n\n\n"
        }
      ]
    }
  ]
}